JPWO2016140216A1 - Solid phase carrier, ligand-bound solid phase carrier, target substance detection or separation method, and method for producing the solid phase carrier - Google Patents
Solid phase carrier, ligand-bound solid phase carrier, target substance detection or separation method, and method for producing the solid phase carrier Download PDFInfo
- Publication number
- JPWO2016140216A1 JPWO2016140216A1 JP2017503659A JP2017503659A JPWO2016140216A1 JP WO2016140216 A1 JPWO2016140216 A1 JP WO2016140216A1 JP 2017503659 A JP2017503659 A JP 2017503659A JP 2017503659 A JP2017503659 A JP 2017503659A JP WO2016140216 A1 JPWO2016140216 A1 JP WO2016140216A1
- Authority
- JP
- Japan
- Prior art keywords
- solid phase
- structural unit
- group
- phase carrier
- ligand
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000003446 ligand Substances 0.000 title claims abstract description 95
- 239000007790 solid phase Substances 0.000 title claims abstract description 79
- 239000013076 target substance Substances 0.000 title claims abstract description 48
- 238000001514 detection method Methods 0.000 title claims description 9
- 238000004519 manufacturing process Methods 0.000 title claims description 7
- 238000000926 separation method Methods 0.000 title description 10
- 239000000178 monomer Substances 0.000 claims abstract description 101
- 125000000524 functional group Chemical group 0.000 claims abstract description 60
- 229920001577 copolymer Polymers 0.000 claims abstract description 35
- 238000000034 method Methods 0.000 claims abstract description 27
- 239000007787 solid Substances 0.000 claims abstract description 17
- 239000002245 particle Substances 0.000 claims description 81
- NIXOWILDQLNWCW-UHFFFAOYSA-M Acrylate Chemical compound [O-]C(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-M 0.000 claims description 37
- 239000000427 antigen Substances 0.000 claims description 24
- 102000036639 antigens Human genes 0.000 claims description 24
- 108091007433 antigens Proteins 0.000 claims description 24
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 24
- 125000000962 organic group Chemical group 0.000 claims description 21
- 125000004432 carbon atom Chemical group C* 0.000 claims description 20
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 19
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 19
- 239000002994 raw material Substances 0.000 claims description 18
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 16
- 239000006249 magnetic particle Substances 0.000 claims description 10
- 102000039446 nucleic acids Human genes 0.000 claims description 10
- 108020004707 nucleic acids Proteins 0.000 claims description 10
- 150000007523 nucleic acids Chemical class 0.000 claims description 10
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 8
- 102000004169 proteins and genes Human genes 0.000 claims description 8
- 108090000623 proteins and genes Proteins 0.000 claims description 8
- 125000000843 phenylene group Chemical group C1(=C(C=CC=C1)*)* 0.000 claims description 7
- 238000010556 emulsion polymerization method Methods 0.000 claims description 6
- 238000003018 immunoassay Methods 0.000 claims description 6
- 238000010526 radical polymerization reaction Methods 0.000 claims description 6
- 125000000217 alkyl group Chemical group 0.000 claims description 5
- 229940079593 drug Drugs 0.000 claims description 5
- 239000003814 drug Substances 0.000 claims description 5
- 229920001519 homopolymer Polymers 0.000 claims description 5
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 claims description 4
- 238000007720 emulsion polymerization reaction Methods 0.000 claims description 4
- 150000004676 glycans Chemical class 0.000 claims description 4
- 229920001282 polysaccharide Polymers 0.000 claims description 4
- 239000005017 polysaccharide Substances 0.000 claims description 4
- 239000000758 substrate Substances 0.000 claims description 4
- 150000001413 amino acids Chemical class 0.000 claims description 3
- 150000002632 lipids Chemical class 0.000 claims description 3
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 3
- 235000000346 sugar Nutrition 0.000 claims description 3
- 239000011782 vitamin Substances 0.000 claims description 3
- 229940088594 vitamin Drugs 0.000 claims description 3
- 229930003231 vitamin Natural products 0.000 claims description 3
- 235000013343 vitamin Nutrition 0.000 claims description 3
- 239000005556 hormone Substances 0.000 claims description 2
- 229940088597 hormone Drugs 0.000 claims description 2
- 239000002777 nucleoside Substances 0.000 claims description 2
- 150000003833 nucleoside derivatives Chemical class 0.000 claims description 2
- 239000002773 nucleotide Substances 0.000 claims description 2
- 125000003729 nucleotide group Chemical group 0.000 claims description 2
- 125000001183 hydrocarbyl group Chemical group 0.000 claims 1
- 239000002858 neurotransmitter agent Substances 0.000 claims 1
- 150000003722 vitamin derivatives Chemical class 0.000 claims 1
- 238000001179 sorption measurement Methods 0.000 abstract description 36
- -1 methane-1,1-diyl group Chemical group 0.000 description 69
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 26
- 150000002430 hydrocarbons Chemical group 0.000 description 23
- 125000001931 aliphatic group Chemical group 0.000 description 19
- 239000000839 emulsion Substances 0.000 description 17
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 16
- 239000007864 aqueous solution Substances 0.000 description 16
- 230000005291 magnetic effect Effects 0.000 description 15
- LCXXNKZQVOXMEH-UHFFFAOYSA-N Tetrahydrofurfuryl methacrylate Chemical compound CC(=C)C(=O)OCC1CCCO1 LCXXNKZQVOXMEH-UHFFFAOYSA-N 0.000 description 14
- 230000001629 suppression Effects 0.000 description 14
- CLSIFQGHPQDTHQ-DTWKUNHWSA-N (2s,3r)-2-[(4-carboxyphenyl)methyl]-3-hydroxybutanedioic acid Chemical compound OC(=O)[C@H](O)[C@@H](C(O)=O)CC1=CC=C(C(O)=O)C=C1 CLSIFQGHPQDTHQ-DTWKUNHWSA-N 0.000 description 12
- 125000002723 alicyclic group Chemical group 0.000 description 11
- 239000011347 resin Substances 0.000 description 10
- 229920005989 resin Polymers 0.000 description 10
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 8
- 125000002029 aromatic hydrocarbon group Chemical group 0.000 description 8
- 229910052799 carbon Inorganic materials 0.000 description 8
- 230000000052 comparative effect Effects 0.000 description 8
- 230000005389 magnetism Effects 0.000 description 8
- 238000012360 testing method Methods 0.000 description 8
- RTZKZFJDLAIYFH-UHFFFAOYSA-N ether Substances CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 7
- 239000010419 fine particle Substances 0.000 description 7
- 239000000696 magnetic material Substances 0.000 description 7
- 239000000126 substance Substances 0.000 description 7
- HRPVXLWXLXDGHG-UHFFFAOYSA-N Acrylamide Chemical group NC(=O)C=C HRPVXLWXLXDGHG-UHFFFAOYSA-N 0.000 description 6
- IUHFWCGCSVTMPG-UHFFFAOYSA-N [C].[C] Chemical group [C].[C] IUHFWCGCSVTMPG-UHFFFAOYSA-N 0.000 description 6
- 125000003277 amino group Chemical group 0.000 description 6
- 230000008569 process Effects 0.000 description 6
- 239000000243 solution Substances 0.000 description 6
- PPBRXRYQALVLMV-UHFFFAOYSA-N Styrene Chemical compound C=CC1=CC=CC=C1 PPBRXRYQALVLMV-UHFFFAOYSA-N 0.000 description 5
- 125000001841 imino group Chemical group [H]N=* 0.000 description 5
- 239000000463 material Substances 0.000 description 5
- 239000000203 mixture Substances 0.000 description 5
- 239000006228 supernatant Substances 0.000 description 5
- 125000002088 tosyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1C([H])([H])[H])S(*)(=O)=O 0.000 description 5
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 4
- MYRTYDVEIRVNKP-UHFFFAOYSA-N 1,2-Divinylbenzene Chemical compound C=CC1=CC=CC=C1C=C MYRTYDVEIRVNKP-UHFFFAOYSA-N 0.000 description 4
- KAKZBPTYRLMSJV-UHFFFAOYSA-N Butadiene Chemical compound C=CC=C KAKZBPTYRLMSJV-UHFFFAOYSA-N 0.000 description 4
- RRHGJUQNOFWUDK-UHFFFAOYSA-N Isoprene Chemical compound CC(=C)C=C RRHGJUQNOFWUDK-UHFFFAOYSA-N 0.000 description 4
- 239000002585 base Substances 0.000 description 4
- 238000007796 conventional method Methods 0.000 description 4
- 238000000113 differential scanning calorimetry Methods 0.000 description 4
- 125000000816 ethylene group Chemical group [H]C([H])([*:1])C([H])([H])[*:2] 0.000 description 4
- 229910052739 hydrogen Inorganic materials 0.000 description 4
- 239000001257 hydrogen Substances 0.000 description 4
- 229920000642 polymer Polymers 0.000 description 4
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 4
- 125000003258 trimethylene group Chemical group [H]C([H])([*:2])C([H])([H])C([H])([H])[*:1] 0.000 description 4
- DTGKSKDOIYIVQL-WEDXCCLWSA-N (+)-borneol Chemical group C1C[C@@]2(C)[C@@H](O)C[C@@H]1C2(C)C DTGKSKDOIYIVQL-WEDXCCLWSA-N 0.000 description 3
- CERQOIWHTDAKMF-UHFFFAOYSA-M Methacrylate Chemical compound CC(=C)C([O-])=O CERQOIWHTDAKMF-UHFFFAOYSA-M 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 239000007771 core particle Substances 0.000 description 3
- QSAWQNUELGIYBC-UHFFFAOYSA-N cyclohexane-1,2-dicarboxylic acid Chemical compound OC(=O)C1CCCCC1C(O)=O QSAWQNUELGIYBC-UHFFFAOYSA-N 0.000 description 3
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 3
- 238000001938 differential scanning calorimetry curve Methods 0.000 description 3
- 239000006185 dispersion Substances 0.000 description 3
- 125000003700 epoxy group Chemical group 0.000 description 3
- 239000011553 magnetic fluid Substances 0.000 description 3
- 230000000630 rising effect Effects 0.000 description 3
- 230000035945 sensitivity Effects 0.000 description 3
- 125000000383 tetramethylene group Chemical group [H]C([H])([*:1])C([H])([H])C([H])([H])C([H])([H])[*:2] 0.000 description 3
- 229920002554 vinyl polymer Polymers 0.000 description 3
- WFSMVVDJSNMRAR-UHFFFAOYSA-N 2-[2-(2-ethoxyethoxy)ethoxy]ethanol Chemical compound CCOCCOCCOCCO WFSMVVDJSNMRAR-UHFFFAOYSA-N 0.000 description 2
- TXBCBTDQIULDIA-UHFFFAOYSA-N 2-[[3-hydroxy-2,2-bis(hydroxymethyl)propoxy]methyl]-2-(hydroxymethyl)propane-1,3-diol Chemical compound OCC(CO)(CO)COCC(CO)(CO)CO TXBCBTDQIULDIA-UHFFFAOYSA-N 0.000 description 2
- 125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 description 2
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 2
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 2
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 2
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 2
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 2
- UQSXHKLRYXJYBZ-UHFFFAOYSA-N Iron oxide Chemical compound [Fe]=O UQSXHKLRYXJYBZ-UHFFFAOYSA-N 0.000 description 2
- 239000007987 MES buffer Substances 0.000 description 2
- CERQOIWHTDAKMF-UHFFFAOYSA-N Methacrylic acid Chemical compound CC(=C)C(O)=O CERQOIWHTDAKMF-UHFFFAOYSA-N 0.000 description 2
- IMNFDUFMRHMDMM-UHFFFAOYSA-N N-Heptane Chemical compound CCCCCCC IMNFDUFMRHMDMM-UHFFFAOYSA-N 0.000 description 2
- PXHVJJICTQNCMI-UHFFFAOYSA-N Nickel Chemical compound [Ni] PXHVJJICTQNCMI-UHFFFAOYSA-N 0.000 description 2
- 239000002202 Polyethylene glycol Substances 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- ZJCCRDAZUWHFQH-UHFFFAOYSA-N Trimethylolpropane Chemical compound CCC(CO)(CO)CO ZJCCRDAZUWHFQH-UHFFFAOYSA-N 0.000 description 2
- 150000001252 acrylic acid derivatives Chemical class 0.000 description 2
- 125000003647 acryloyl group Chemical group O=C([*])C([H])=C([H])[H] 0.000 description 2
- 239000000908 ammonium hydroxide Substances 0.000 description 2
- 125000000129 anionic group Chemical group 0.000 description 2
- 239000004019 antithrombin Substances 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 229960002685 biotin Drugs 0.000 description 2
- 235000020958 biotin Nutrition 0.000 description 2
- 239000011616 biotin Substances 0.000 description 2
- 239000000969 carrier Substances 0.000 description 2
- 125000002091 cationic group Chemical group 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 description 2
- 229960001231 choline Drugs 0.000 description 2
- 238000002425 crystallisation Methods 0.000 description 2
- 230000008025 crystallization Effects 0.000 description 2
- 125000000753 cycloalkyl group Chemical group 0.000 description 2
- 238000003745 diagnosis Methods 0.000 description 2
- 150000001993 dienes Chemical class 0.000 description 2
- 239000012153 distilled water Substances 0.000 description 2
- 229940088598 enzyme Drugs 0.000 description 2
- 125000001301 ethoxy group Chemical group [H]C([H])([H])C([H])([H])O* 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 239000012894 fetal calf serum Substances 0.000 description 2
- 150000002431 hydrogen Chemical class 0.000 description 2
- AMWRITDGCCNYAT-UHFFFAOYSA-L hydroxy(oxo)manganese;manganese Chemical compound [Mn].O[Mn]=O.O[Mn]=O AMWRITDGCCNYAT-UHFFFAOYSA-L 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 239000003999 initiator Substances 0.000 description 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 2
- 239000011572 manganese Substances 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 238000000691 measurement method Methods 0.000 description 2
- 229910052751 metal Inorganic materials 0.000 description 2
- 239000002184 metal Substances 0.000 description 2
- RXRHXOLQBOFMDI-UHFFFAOYSA-N methoxymethane;2-methylprop-2-enoic acid Chemical compound COC.CC(=C)C(O)=O RXRHXOLQBOFMDI-UHFFFAOYSA-N 0.000 description 2
- FCFDFAVHZMMDEO-UHFFFAOYSA-N methoxymethane;prop-2-enoic acid Chemical compound COC.OC(=O)C=C FCFDFAVHZMMDEO-UHFFFAOYSA-N 0.000 description 2
- 125000002950 monocyclic group Chemical group 0.000 description 2
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 2
- 239000008188 pellet Substances 0.000 description 2
- 239000012071 phase Substances 0.000 description 2
- 125000005328 phosphinyl group Chemical group [PH2](=O)* 0.000 description 2
- XNGIFLGASWRNHJ-UHFFFAOYSA-M phthalate(1-) Chemical compound OC(=O)C1=CC=CC=C1C([O-])=O XNGIFLGASWRNHJ-UHFFFAOYSA-M 0.000 description 2
- XNGIFLGASWRNHJ-UHFFFAOYSA-N phthalic acid Chemical compound OC(=O)C1=CC=CC=C1C(O)=O XNGIFLGASWRNHJ-UHFFFAOYSA-N 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- 238000006116 polymerization reaction Methods 0.000 description 2
- 102000004196 processed proteins & peptides Human genes 0.000 description 2
- 150000003242 quaternary ammonium salts Chemical class 0.000 description 2
- 229920005604 random copolymer Polymers 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 125000004079 stearyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
- KDYFGRWQOYBRFD-UHFFFAOYSA-M succinate(1-) Chemical compound OC(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-M 0.000 description 2
- KDYFGRWQOYBRFD-UHFFFAOYSA-N succinic acid Chemical compound OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 2
- 150000008163 sugars Chemical class 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- 229910000859 α-Fe Inorganic materials 0.000 description 2
- JWDFQMWEFLOOED-UHFFFAOYSA-N (2,5-dioxopyrrolidin-1-yl) 3-(pyridin-2-yldisulfanyl)propanoate Chemical compound O=C1CCC(=O)N1OC(=O)CCSSC1=CC=CC=N1 JWDFQMWEFLOOED-UHFFFAOYSA-N 0.000 description 1
- LMDZBCPBFSXMTL-UHFFFAOYSA-N 1-Ethyl-3-(3-dimethylaminopropyl)carbodiimide Substances CCN=C=NCCCN(C)C LMDZBCPBFSXMTL-UHFFFAOYSA-N 0.000 description 1
- QAPSNMNOIOSXSQ-YNEHKIRRSA-N 1-[(2r,4s,5r)-4-[tert-butyl(dimethyl)silyl]oxy-5-(hydroxymethyl)oxolan-2-yl]-5-methylpyrimidine-2,4-dione Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O[Si](C)(C)C(C)(C)C)C1 QAPSNMNOIOSXSQ-YNEHKIRRSA-N 0.000 description 1
- STMDPCBYJCIZOD-UHFFFAOYSA-N 2-(2,4-dinitroanilino)-4-methylpentanoic acid Chemical compound CC(C)CC(C(O)=O)NC1=CC=C([N+]([O-])=O)C=C1[N+]([O-])=O STMDPCBYJCIZOD-UHFFFAOYSA-N 0.000 description 1
- DAVVKEZTUOGEAK-UHFFFAOYSA-N 2-(2-methoxyethoxy)ethyl 2-methylprop-2-enoate Chemical compound COCCOCCOC(=O)C(C)=C DAVVKEZTUOGEAK-UHFFFAOYSA-N 0.000 description 1
- LBNDGEZENJUBCO-UHFFFAOYSA-N 2-[2-(2-methylprop-2-enoyloxy)ethyl]butanedioic acid Chemical compound CC(=C)C(=O)OCCC(C(O)=O)CC(O)=O LBNDGEZENJUBCO-UHFFFAOYSA-N 0.000 description 1
- UZMZRFVLRULBOV-UHFFFAOYSA-N 2-[dimethyl-[2-(2-methylprop-2-enoyloxy)ethyl]azaniumyl]acetate Chemical compound CC(=C)C(=O)OCC[N+](C)(C)CC([O-])=O UZMZRFVLRULBOV-UHFFFAOYSA-N 0.000 description 1
- 125000000022 2-aminoethyl group Chemical group [H]C([*])([H])C([H])([H])N([H])[H] 0.000 description 1
- YXYJVFYWCLAXHO-UHFFFAOYSA-N 2-methoxyethyl 2-methylprop-2-enoate Chemical compound COCCOC(=O)C(C)=C YXYJVFYWCLAXHO-UHFFFAOYSA-N 0.000 description 1
- HFCUBKYHMMPGBY-UHFFFAOYSA-N 2-methoxyethyl prop-2-enoate Chemical compound COCCOC(=O)C=C HFCUBKYHMMPGBY-UHFFFAOYSA-N 0.000 description 1
- KFGFVPMRLOQXNB-UHFFFAOYSA-N 3,5,5-trimethylhexanoyl 3,5,5-trimethylhexaneperoxoate Chemical compound CC(C)(C)CC(C)CC(=O)OOC(=O)CC(C)CC(C)(C)C KFGFVPMRLOQXNB-UHFFFAOYSA-N 0.000 description 1
- FPQQSJJWHUJYPU-UHFFFAOYSA-N 3-(dimethylamino)propyliminomethylidene-ethylazanium;chloride Chemical compound Cl.CCN=C=NCCCN(C)C FPQQSJJWHUJYPU-UHFFFAOYSA-N 0.000 description 1
- OXOWTLDONRGYOT-UHFFFAOYSA-N 4-(dimethylamino)butanoic acid Chemical compound CN(C)CCCC(O)=O OXOWTLDONRGYOT-UHFFFAOYSA-N 0.000 description 1
- 229920000936 Agarose Polymers 0.000 description 1
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 1
- 102000007592 Apolipoproteins Human genes 0.000 description 1
- 108010071619 Apolipoproteins Proteins 0.000 description 1
- 108090001008 Avidin Proteins 0.000 description 1
- 108010017384 Blood Proteins Proteins 0.000 description 1
- 102000004506 Blood Proteins Human genes 0.000 description 1
- BHPQYMZQTOCNFJ-UHFFFAOYSA-N Calcium cation Chemical compound [Ca+2] BHPQYMZQTOCNFJ-UHFFFAOYSA-N 0.000 description 1
- 239000004215 Carbon black (E152) Substances 0.000 description 1
- 206010009944 Colon cancer Diseases 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- 239000003154 D dimer Substances 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- DKMROQRQHGEIOW-UHFFFAOYSA-N Diethyl succinate Chemical compound CCOC(=O)CCC(=O)OCC DKMROQRQHGEIOW-UHFFFAOYSA-N 0.000 description 1
- 238000008416 Ferritin Methods 0.000 description 1
- 208000031886 HIV Infections Diseases 0.000 description 1
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
- 241000714260 Human T-lymphotropic virus 1 Species 0.000 description 1
- 241000713772 Human immunodeficiency virus 1 Species 0.000 description 1
- 241000713340 Human immunodeficiency virus 2 Species 0.000 description 1
- 102000004877 Insulin Human genes 0.000 description 1
- 108090001061 Insulin Proteins 0.000 description 1
- 102000004856 Lectins Human genes 0.000 description 1
- 108090001090 Lectins Proteins 0.000 description 1
- JLVVSXFLKOJNIY-UHFFFAOYSA-N Magnesium ion Chemical compound [Mg+2] JLVVSXFLKOJNIY-UHFFFAOYSA-N 0.000 description 1
- 241000204031 Mycoplasma Species 0.000 description 1
- FFDGPVCHZBVARC-UHFFFAOYSA-N N,N-dimethylglycine Chemical compound CN(C)CC(O)=O FFDGPVCHZBVARC-UHFFFAOYSA-N 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 229920001213 Polysorbate 20 Polymers 0.000 description 1
- 239000004793 Polystyrene Substances 0.000 description 1
- NPYPAHLBTDXSSS-UHFFFAOYSA-N Potassium ion Chemical compound [K+] NPYPAHLBTDXSSS-UHFFFAOYSA-N 0.000 description 1
- BLRPTPMANUNPDV-UHFFFAOYSA-N Silane Chemical compound [SiH4] BLRPTPMANUNPDV-UHFFFAOYSA-N 0.000 description 1
- FKNQFGJONOIPTF-UHFFFAOYSA-N Sodium cation Chemical compound [Na+] FKNQFGJONOIPTF-UHFFFAOYSA-N 0.000 description 1
- 101710120037 Toxin CcdB Proteins 0.000 description 1
- 241000223996 Toxoplasma Species 0.000 description 1
- OKKRPWIIYQTPQF-UHFFFAOYSA-N Trimethylolpropane trimethacrylate Chemical compound CC(=C)C(=O)OCC(CC)(COC(=O)C(C)=C)COC(=O)C(C)=C OKKRPWIIYQTPQF-UHFFFAOYSA-N 0.000 description 1
- 239000013504 Triton X-100 Substances 0.000 description 1
- 229920004890 Triton X-100 Polymers 0.000 description 1
- 238000004833 X-ray photoelectron spectroscopy Methods 0.000 description 1
- YIMQCDZDWXUDCA-UHFFFAOYSA-N [4-(hydroxymethyl)cyclohexyl]methanol Chemical compound OCC1CCC(CO)CC1 YIMQCDZDWXUDCA-UHFFFAOYSA-N 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 239000012190 activator Substances 0.000 description 1
- 229910001413 alkali metal ion Inorganic materials 0.000 description 1
- 229910001420 alkaline earth metal ion Inorganic materials 0.000 description 1
- 229910045601 alloy Inorganic materials 0.000 description 1
- 239000000956 alloy Substances 0.000 description 1
- XYLMUPLGERFSHI-UHFFFAOYSA-N alpha-Methylstyrene Chemical compound CC(=C)C1=CC=CC=C1 XYLMUPLGERFSHI-UHFFFAOYSA-N 0.000 description 1
- 229920005603 alternating copolymer Polymers 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000002494 anti-cea effect Effects 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 230000010100 anticoagulation Effects 0.000 description 1
- 239000012736 aqueous medium Substances 0.000 description 1
- 125000003118 aryl group Chemical group 0.000 description 1
- 125000000732 arylene group Chemical group 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 230000005784 autoimmunity Effects 0.000 description 1
- IVRMZWNICZWHMI-UHFFFAOYSA-N azide group Chemical group [N-]=[N+]=[N-] IVRMZWNICZWHMI-UHFFFAOYSA-N 0.000 description 1
- 239000011324 bead Substances 0.000 description 1
- 230000001588 bifunctional effect Effects 0.000 description 1
- 229920001400 block copolymer Polymers 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 229910001424 calcium ion Inorganic materials 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 229910017052 cobalt Inorganic materials 0.000 description 1
- 239000010941 cobalt Substances 0.000 description 1
- GUTLYIVDDKVIGB-UHFFFAOYSA-N cobalt atom Chemical compound [Co] GUTLYIVDDKVIGB-UHFFFAOYSA-N 0.000 description 1
- 229910000428 cobalt oxide Inorganic materials 0.000 description 1
- IVMYJDGYRUAWML-UHFFFAOYSA-N cobalt(ii) oxide Chemical compound [Co]=O IVMYJDGYRUAWML-UHFFFAOYSA-N 0.000 description 1
- 208000029742 colonic neoplasm Diseases 0.000 description 1
- 239000000356 contaminant Substances 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- OIWOHHBRDFKZNC-UHFFFAOYSA-N cyclohexyl 2-methylprop-2-enoate Chemical compound CC(=C)C(=O)OC1CCCCC1 OIWOHHBRDFKZNC-UHFFFAOYSA-N 0.000 description 1
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 229960005156 digoxin Drugs 0.000 description 1
- YSCHCBVNGBHFJV-UHFFFAOYSA-N dimethyl(3-sulfopropyl)azanium hydroxide Chemical compound [OH-].C[NH+](C)CCCS(O)(=O)=O YSCHCBVNGBHFJV-UHFFFAOYSA-N 0.000 description 1
- ROSDSFDQCJNGOL-UHFFFAOYSA-O dimethylaminium Chemical compound C[NH2+]C ROSDSFDQCJNGOL-UHFFFAOYSA-O 0.000 description 1
- KAKKHKRHCKCAGH-UHFFFAOYSA-L disodium;(4-nitrophenyl) phosphate;hexahydrate Chemical compound O.O.O.O.O.O.[Na+].[Na+].[O-][N+](=O)C1=CC=C(OP([O-])([O-])=O)C=C1 KAKKHKRHCKCAGH-UHFFFAOYSA-L 0.000 description 1
- 239000003596 drug target Substances 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 238000000921 elemental analysis Methods 0.000 description 1
- 230000007368 endocrine function Effects 0.000 description 1
- MMVJBWFKSYKXIA-UHFFFAOYSA-N ethoxyethane;2-methylprop-2-enoic acid Chemical compound CCOCC.CC(=C)C(O)=O MMVJBWFKSYKXIA-UHFFFAOYSA-N 0.000 description 1
- LVMRFLWAXIZLNG-UHFFFAOYSA-N ethoxyethane;prop-2-enoic acid Chemical compound CCOCC.OC(=O)C=C LVMRFLWAXIZLNG-UHFFFAOYSA-N 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 230000005294 ferromagnetic effect Effects 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 230000020764 fibrinolysis Effects 0.000 description 1
- 230000004907 flux Effects 0.000 description 1
- 238000005227 gel permeation chromatography Methods 0.000 description 1
- 125000003055 glycidyl group Chemical group C(C1CO1)* 0.000 description 1
- 125000003827 glycol group Chemical group 0.000 description 1
- 238000010559 graft polymerization reaction Methods 0.000 description 1
- 229920000669 heparin Polymers 0.000 description 1
- 229960002897 heparin Drugs 0.000 description 1
- 125000003187 heptyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 238000009396 hybridization Methods 0.000 description 1
- 229930195733 hydrocarbon Natural products 0.000 description 1
- GPRLSGONYQIRFK-UHFFFAOYSA-N hydron Chemical compound [H+] GPRLSGONYQIRFK-UHFFFAOYSA-N 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-M hydroxide Chemical compound [OH-] XLYOFNOQVPJJNP-UHFFFAOYSA-M 0.000 description 1
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 1
- 230000036046 immunoreaction Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 229910010272 inorganic material Inorganic materials 0.000 description 1
- 239000011147 inorganic material Substances 0.000 description 1
- 229940125396 insulin Drugs 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- 239000002523 lectin Substances 0.000 description 1
- 229960004194 lidocaine Drugs 0.000 description 1
- 230000031700 light absorption Effects 0.000 description 1
- 229910001425 magnesium ion Inorganic materials 0.000 description 1
- WPBNNNQJVZRUHP-UHFFFAOYSA-L manganese(2+);methyl n-[[2-(methoxycarbonylcarbamothioylamino)phenyl]carbamothioyl]carbamate;n-[2-(sulfidocarbothioylamino)ethyl]carbamodithioate Chemical compound [Mn+2].[S-]C(=S)NCCNC([S-])=S.COC(=O)NC(=S)NC1=CC=CC=C1NC(=S)NC(=O)OC WPBNNNQJVZRUHP-UHFFFAOYSA-L 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 229910044991 metal oxide Inorganic materials 0.000 description 1
- 150000004706 metal oxides Chemical class 0.000 description 1
- 150000002739 metals Chemical class 0.000 description 1
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000004957 naphthylene group Chemical group 0.000 description 1
- 229920005615 natural polymer Polymers 0.000 description 1
- 229910052759 nickel Inorganic materials 0.000 description 1
- 229910000480 nickel oxide Inorganic materials 0.000 description 1
- 239000007764 o/w emulsion Substances 0.000 description 1
- 125000002347 octyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 239000011368 organic material Substances 0.000 description 1
- GNRSAWUEBMWBQH-UHFFFAOYSA-N oxonickel Chemical compound [Ni]=O GNRSAWUEBMWBQH-UHFFFAOYSA-N 0.000 description 1
- 230000005298 paramagnetic effect Effects 0.000 description 1
- 125000001147 pentyl group Chemical group C(CCCC)* 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 150000002978 peroxides Chemical class 0.000 description 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 1
- XNGIFLGASWRNHJ-UHFFFAOYSA-L phthalate(2-) Chemical compound [O-]C(=O)C1=CC=CC=C1C([O-])=O XNGIFLGASWRNHJ-UHFFFAOYSA-L 0.000 description 1
- 210000002381 plasma Anatomy 0.000 description 1
- 239000003505 polymerization initiator Substances 0.000 description 1
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 1
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 1
- 229920002223 polystyrene Polymers 0.000 description 1
- 239000011148 porous material Substances 0.000 description 1
- 229910001414 potassium ion Inorganic materials 0.000 description 1
- 239000011164 primary particle Substances 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 238000003127 radioimmunoassay Methods 0.000 description 1
- 239000012966 redox initiator Substances 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 229910000077 silane Inorganic materials 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 229910001415 sodium ion Inorganic materials 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 150000003440 styrenes Chemical class 0.000 description 1
- 239000001384 succinic acid Substances 0.000 description 1
- 238000010557 suspension polymerization reaction Methods 0.000 description 1
- 229920001059 synthetic polymer Polymers 0.000 description 1
- MUTNCGKQJGXKEM-UHFFFAOYSA-N tamibarotene Chemical compound C=1C=C2C(C)(C)CCC(C)(C)C2=CC=1NC(=O)C1=CC=C(C(O)=O)C=C1 MUTNCGKQJGXKEM-UHFFFAOYSA-N 0.000 description 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 125000005413 thiopyridyl group Chemical group 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08F—MACROMOLECULAR COMPOUNDS OBTAINED BY REACTIONS ONLY INVOLVING CARBON-TO-CARBON UNSATURATED BONDS
- C08F220/00—Copolymers of compounds having one or more unsaturated aliphatic radicals, each having only one carbon-to-carbon double bond, and only one being terminated by only one carboxyl radical or a salt, anhydride ester, amide, imide or nitrile thereof
- C08F220/02—Monocarboxylic acids having less than ten carbon atoms; Derivatives thereof
- C08F220/10—Esters
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
Abstract
簡便な手法で製造でき、非特異吸着が発生しにくく、リガンドを結合した場合に優れた標的物質捕捉性能を示す固相担体を提供すること。以下の構造単位(A)〜(C)を含む共重合体が少なくとも固相の表面を形成することを特徴とする、固相担体。(A)双性イオン構造を有するモノマーに由来する構造単位:全構造単位に対して1〜35質量%(B)リガンドと化学結合可能な官能基を有するモノマーに由来する構造単位:全構造単位に対して70質量%以下(C)リガンドと化学結合可能な官能基を有さない水難溶性モノマーに由来する構造単位To provide a solid phase carrier that can be produced by a simple method, hardly causes non-specific adsorption, and exhibits excellent target substance capturing performance when a ligand is bound thereto. A solid phase carrier, wherein a copolymer comprising the following structural units (A) to (C) forms at least a solid surface. (A) Structural unit derived from a monomer having a zwitterionic structure: 1 to 35% by mass relative to all structural units (B) Structural unit derived from a monomer having a functional group capable of chemically bonding to a ligand: all structural units 70% by mass or less based on (C) a structural unit derived from a poorly water-soluble monomer having no functional group capable of chemically bonding to a ligand
Description
本発明は、固相担体、リガンド結合固相担体、標的物質の検出又は分離方法、及び前記固相担体の製造方法に関する。 The present invention relates to a solid phase carrier, a ligand-bound solid phase carrier, a method for detecting or separating a target substance, and a method for producing the solid phase carrier.
タンパク質、核酸、細胞等の標的物質を血液等の試料から検出・分離することを目的として固相担体が利用されている。固相担体を用いた検出・分離法としては、固相担体にリガンドを結合させ、これに試料を接触させることによって標的物質をリガンドと反応させる方法が一般的であるが、上記接触の際に、試料中の標的物質や夾雑物が、リガンドではなく固相担体の表面に非特異的に吸着しこれがノイズとなる場合がある。 Solid phase carriers are used for the purpose of detecting and separating target substances such as proteins, nucleic acids and cells from samples such as blood. As a detection / separation method using a solid phase carrier, a method is generally used in which a ligand is bound to a solid phase carrier and a sample is brought into contact therewith to cause a target substance to react with the ligand. In some cases, target substances and contaminants in the sample are adsorbed nonspecifically on the surface of the solid phase carrier, not the ligand, and this causes noise.
そのため、リガンドと化学結合可能な官能基を有するモノマーとともに、双性イオン構造を有するモノマーや一定以上の長さのポリエチレングリコール鎖を有するモノマーといった親水性の高いモノマーを用いた共重合体を固相担体の表面に形成させることで、その表面の親水性を高めることにより、非特異吸着を抑制する試みがなされている(特許文献1〜3)。 For this reason, a copolymer using a highly hydrophilic monomer such as a monomer having a functional group capable of chemically bonding to a ligand and a zwitterionic structure or a monomer having a polyethylene glycol chain of a certain length or more is used as a solid phase. Attempts have been made to suppress non-specific adsorption by increasing the hydrophilicity of the surface by forming it on the surface of the carrier (Patent Documents 1 to 3).
しかしながら、上記のような親水性の高いモノマーを用いて固相担体表面の親水性を高めるのみでは、非特異吸着を充分に抑制するには至らず、また、リガンドを結合して用いた場合の標的物質の捕捉量にも改善の余地があった。
また、特許文献2及び3では、放射線照射グラフト重合法やシランカップリング法を利用して固相担体の表面に共重合体を結合させているが、斯様なグラフト化等の特殊な手法を利用しなくても簡便に製造できる固相担体の開発が望まれる。固相担体の表面に共重合体を形成させる簡便な手法として乳化重合法が知られているが(特許文献4)、親水性の高いモノマー由来の構造単位を含む重合体を乳化重合法で固相担体の表面に形成させることは困難であり、乳化重合法のような簡便な手法で製造できることと、非特異吸着を充分に抑制させることを両立させるのは難しかった。However, simply increasing the hydrophilicity of the solid phase carrier surface using a highly hydrophilic monomer as described above does not sufficiently suppress non-specific adsorption. There was also room for improvement in the capture amount of the target substance.
In Patent Documents 2 and 3, a copolymer is bonded to the surface of a solid support using a radiation-induced graft polymerization method or a silane coupling method, but a special technique such as grafting is used. It is desired to develop a solid support that can be easily produced without using it. An emulsion polymerization method is known as a simple technique for forming a copolymer on the surface of a solid phase carrier (Patent Document 4). A polymer containing a structural unit derived from a highly hydrophilic monomer is solidified by an emulsion polymerization method. It is difficult to form it on the surface of the phase carrier, and it has been difficult to satisfy both the fact that it can be produced by a simple technique such as an emulsion polymerization method and sufficiently suppressing nonspecific adsorption.
したがって、本発明が解決しようとする課題は、簡便な手法で製造でき、非特異吸着が発生しにくく、リガンドを結合した場合に優れた標的物質捕捉性能を示す固相担体を提供することにある。 Therefore, the problem to be solved by the present invention is to provide a solid phase carrier that can be produced by a simple method, hardly causes non-specific adsorption, and exhibits excellent target substance capturing performance when a ligand is bound thereto. .
そこで、本発明者らは鋭意検討した結果、(A)双性イオン構造を有するモノマーに由来する構造単位:全構造単位に対して1〜35質量%と、(B)リガンドと化学結合可能な官能基を有するモノマーに由来する構造単位:全構造単位に対して70質量%以下と、(C)リガンドと化学結合可能な官能基を有さない水難溶性モノマーに由来する構造単位とを含む共重合体が少なくとも固相の表面を形成することを特徴とする固相担体が、乳化重合法を利用して簡便に製造でき、非特異吸着が発生しにくく、リガンドを結合した場合に優れた標的物質捕捉性能を示すことを見出し、本発明を完成した。 Therefore, as a result of intensive studies, the present inventors have found that (A) a structural unit derived from a monomer having a zwitterionic structure: 1 to 35% by mass with respect to all structural units, and (B) a chemical bond with a ligand. A structural unit derived from a monomer having a functional group: a copolymer comprising 70% by mass or less with respect to all structural units, and (C) a structural unit derived from a poorly water-soluble monomer having no functional group capable of chemically bonding to a ligand. A solid-phase carrier characterized in that the polymer forms at least a solid-phase surface can be easily produced using an emulsion polymerization method, non-specific adsorption hardly occurs, and an excellent target when a ligand is bound. The present invention was completed by finding that it exhibits a substance-trapping performance.
すなわち、本発明は、以下の<1>〜<4>を提供するものである。 That is, the present invention provides the following <1> to <4>.
<1> 以下の構造単位(A)〜(C)を含む共重合体が少なくとも固相の表面を形成することを特徴とする、固相担体。
(A)双性イオン構造を有するモノマーに由来する構造単位:全構造単位に対して1〜35質量%
(B)リガンドと化学結合可能な官能基を有するモノマーに由来する構造単位:全構造単位に対して70質量%以下
(C)リガンドと化学結合可能な官能基を有さない水難溶性モノマーに由来する構造単位<1> A solid phase carrier, wherein a copolymer containing the following structural units (A) to (C) forms at least a solid surface.
(A) Structural unit derived from a monomer having a zwitterionic structure: 1 to 35% by mass relative to all structural units
(B) Structural unit derived from a monomer having a functional group capable of chemically binding to a ligand: 70% by mass or less based on the total structural unit (C) Derived from a poorly water-soluble monomer having no functional group capable of chemically binding to a ligand Structural unit
<2> 上記<1>の固相担体にリガンドを結合させてなる、リガンド結合固相担体。 <2> A ligand-bound solid phase carrier obtained by binding a ligand to the solid phase carrier of <1> above.
<3> 上記<2>のリガンド結合固相担体を用いることを特徴とする、試料中の標的物質を検出又は分離する方法。 <3> A method for detecting or separating a target substance in a sample, comprising using the ligand-bound solid phase carrier according to <2>.
<4> 双性イオン構造を有するモノマー:全モノマーに対して1〜35質量%と、リガンドと化学結合可能な官能基を有するモノマー:全モノマーに対して70質量%以下と、リガンドと化学結合可能な官能基を有さない水難溶性モノマーとを、原料担体の存在下でラジカル重合させる工程を含むことを特徴とする、固相担体の製造方法。 <4> Monomer having a zwitterionic structure: 1 to 35% by mass with respect to all monomers, and a monomer having a functional group capable of chemically bonding with a ligand: 70% by mass or less with respect to all monomers, and chemical bonding with the ligand A method for producing a solid phase carrier, comprising a step of radical polymerization of a poorly water-soluble monomer having no functional group in the presence of a raw material carrier.
本発明の固相担体は、簡便な手法で製造できる。しかも、非特異吸着が発生しにくく、リガンドを結合した場合に優れた標的物質捕捉性能を示すため、本発明の固相担体にリガンドを結合して用いることによって、高感度且つ低ノイズで標的物質の検出等を行うことができる。
また、本発明の製造方法によれば、非特異吸着が発生しにくく、リガンドを結合した場合に優れた標的物質捕捉性能を示す固相担体を簡便に製造できる。The solid phase carrier of the present invention can be produced by a simple method. In addition, non-specific adsorption is unlikely to occur, and excellent target substance capture performance is exhibited when a ligand is bound. Therefore, the target substance is bound to the solid support of the present invention with high sensitivity and low noise. Can be detected.
In addition, according to the production method of the present invention, a non-specific adsorption is unlikely to occur, and a solid phase carrier that exhibits excellent target substance capturing performance when a ligand is bound can be easily produced.
〔固相担体〕
本発明の固相担体は、以下の構造単位(A)〜(C)を含む共重合体(以下、共重合体(I)とも称する)が少なくとも固相の表面を形成することを特徴とするものである。ここで、本明細書において、「固相の表面を形成する」とは、固相(基材)そのものが共重合体(I)を含むこと、或いは共重合体(I)で固相(基材)が物理的に被覆されることなどによって、共重合体(I)が固相の表面を形成することいい、共重合体(I)が固相表面から形成されるグラフト鎖であることを除く概念である。
(A)双性イオン構造を有するモノマーに由来する構造単位:全構造単位に対して1〜35質量%
(B)リガンドと化学結合可能な官能基を有するモノマーに由来する構造単位:全構造単位に対して70質量%以下
(C)リガンドと化学結合可能な官能基を有さない水難溶性モノマーに由来する構造単位[Solid support]
The solid phase carrier of the present invention is characterized in that a copolymer containing the following structural units (A) to (C) (hereinafter also referred to as copolymer (I)) forms at least a solid surface. Is. Here, in this specification, “form the surface of the solid phase” means that the solid phase (base material) itself contains the copolymer (I) or the copolymer (I) is a solid phase (group). It is said that the copolymer (I) forms a solid phase surface by, for example, being physically coated with the material), and that the copolymer (I) is a graft chain formed from the solid surface. It is a concept to exclude.
(A) Structural unit derived from a monomer having a zwitterionic structure: 1 to 35% by mass relative to all structural units
(B) Structural unit derived from a monomer having a functional group capable of chemically binding to a ligand: 70% by mass or less based on the total structural unit (C) Derived from a poorly water-soluble monomer having no functional group capable of chemically binding to a ligand Structural unit
<構造単位(A)>
共重合体(I)は、双性イオン構造を有するモノマーに由来する構造単位を、全構造単位に対して1〜35質量%含む。斯かる構造単位に含まれる双性イオン構造により、固相担体表面の親水性を高めることができ、非特異吸着が抑制される。なお、構造単位(A)は、ナトリウムイオン、カリウムイオン等のアルカリ金属イオン、カルシウムイオン、マグネシウムイオン等のアルカリ土類金属イオン、アンモニウムイオン、水素イオン、水酸化物イオン等の対イオンを有していてもよい。以下いずれの態様においても同様である。<Structural unit (A)>
Copolymer (I) contains 1 to 35% by mass of structural units derived from a monomer having a zwitterionic structure based on the total structural units. Due to the zwitterionic structure contained in such a structural unit, the hydrophilicity of the solid support surface can be increased, and nonspecific adsorption is suppressed. The structural unit (A) has an alkali metal ion such as sodium ion and potassium ion, an alkaline earth metal ion such as calcium ion and magnesium ion, a counter ion such as ammonium ion, hydrogen ion and hydroxide ion. It may be. The same applies to any of the following embodiments.
双性イオン構造を有するモノマーに由来する構造単位としては、例えば、双性イオン構造を有する(メタ)アクリレート系モノマーに由来する構造単位、双性イオン構造を有する(メタ)アクリルアミド系モノマーに由来する構造単位、双性イオン構造を有するスチレン系モノマーに由来する構造単位が挙げられ、これらのうち1種を含んでいてもよく、2種以上を含んでいてもよい。
これらの中でも、非特異吸着抑制の観点から、双性イオン構造を有する(メタ)アクリレート系モノマーに由来する構造単位、双性イオン構造を有する(メタ)アクリルアミド系モノマーに由来する構造単位が好ましく、双性イオン構造を有する(メタ)アクリレート系モノマーに由来する構造単位がより好ましい。Examples of the structural unit derived from a monomer having a zwitterionic structure include a structural unit derived from a (meth) acrylate monomer having a zwitterionic structure and a (meth) acrylamide monomer having a zwitterionic structure. The structural unit derived from the structural unit and the styrene-type monomer which has a zwitterionic structure is mentioned, Among these, 1 type may be included and 2 or more types may be included.
Among these, from the viewpoint of suppressing non-specific adsorption, a structural unit derived from a (meth) acrylate monomer having a zwitterionic structure, a structural unit derived from a (meth) acrylamide monomer having a zwitterionic structure is preferable, A structural unit derived from a (meth) acrylate monomer having a zwitterionic structure is more preferable.
双性イオン構造としては、非特異吸着抑制の観点から、第4級アンモニウム塩型カチオン性官能基と、−(C=O)O-、−SO3 -及び−O−(O=P−O-)−O−から選ばれる1価又は2価のアニオン性官能基とを有するものが好ましく、下記式(1)又は(2)で表されるものが特に好ましい。The zwitterionic structure includes a quaternary ammonium salt type cationic functional group, — (C═O) O − , —SO 3 — and —O— (O═PO) from the viewpoint of suppressing nonspecific adsorption. - ) Having a monovalent or divalent anionic functional group selected from -O- is preferred, and those represented by the following formula (1) or (2) are particularly preferred.
〔式(1)中、
R1及びR2は、それぞれ独立して、単結合又は炭素数1〜10の2価の有機基を示し、
R3は、−(C=O)O-又は−SO3 -を示し、
R4及びR5は、それぞれ独立して、メチル基又はエチル基を示す。〕[In Formula (1),
R 1 and R 2 each independently represent a single bond or a divalent organic group having 1 to 10 carbon atoms,
R 3 represents — (C═O) O 2 — or —SO 3 — ,
R 4 and R 5 each independently represents a methyl group or an ethyl group. ]
〔式(2)中、
R6及びR7は、それぞれ独立して、単結合又は炭素数1〜10の2価の有機基を示し、
R8、R9及びR10は、それぞれ独立して、メチル基又はエチル基を示す。〕[In Formula (2),
R 6 and R 7 each independently represents a single bond or a divalent organic group having 1 to 10 carbon atoms,
R 8 , R 9 and R 10 each independently represent a methyl group or an ethyl group. ]
式(1)中のR1及びR2、式(2)中のR6及びR7は、それぞれ独立して、単結合又は炭素数1〜10の2価の有機基を示すが、非特異吸着抑制の観点から、炭素数1〜10の2価の有機基が好ましい。当該有機基としては、2価の炭化水素基、炭素数2以上の2価の炭化水素基の炭素−炭素原子間にエーテル結合、アミド結合及びエステル結合から選ばれる1種以上を有する基が好ましく、2価の炭化水素基がより好ましい。R 1 and R 2 in formula (1) and R 6 and R 7 in formula (2) each independently represent a single bond or a divalent organic group having 1 to 10 carbon atoms. From the viewpoint of suppressing adsorption, a divalent organic group having 1 to 10 carbon atoms is preferable. The organic group is preferably a divalent hydrocarbon group or a group having at least one selected from an ether bond, an amide bond and an ester bond between carbon-carbon atoms of a divalent hydrocarbon group having 2 or more carbon atoms. A divalent hydrocarbon group is more preferred.
2価の有機基が2価の炭化水素基である場合、その炭素数としては、1〜8が好ましく、1〜6がより好ましく、1〜4が更に好ましく、1〜3が特に好ましい。一方、2価の有機基が炭素数2以上の2価の炭化水素基の炭素−炭素原子間にエーテル結合、アミド結合及びエステル結合から選ばれる1種以上を有する基である場合、その合計炭素数としては、2〜8が好ましく、2〜6がより好ましく、2〜4が更に好ましく、2又は3が特に好ましい。 When the divalent organic group is a divalent hydrocarbon group, the carbon number is preferably 1 to 8, more preferably 1 to 6, still more preferably 1 to 4, and particularly preferably 1 to 3. On the other hand, when the divalent organic group is a group having one or more selected from an ether bond, an amide bond and an ester bond between carbon-carbon atoms of a divalent hydrocarbon group having 2 or more carbon atoms, the total carbon As a number, 2-8 are preferable, 2-6 are more preferable, 2-4 are still more preferable, and 2 or 3 is especially preferable.
R1、R2、R6及びR7における「2価の炭化水素基」としては、2価の脂肪族炭化水素基が好ましい。当該2価の脂肪族炭化水素基は直鎖状でも分岐鎖状でもよい。
上記2価の脂肪族炭化水素基としては、アルカンジイル基が好ましく、具体的には、メタン−1,1−ジイル基、エタン−1,1−ジイル基、エタン−1,2−ジイル基、プロパン−1,1−ジイル基、プロパン−1,2−ジイル基、プロパン−1,3−ジイル基、プロパン−2,2−ジイル基、ブタン−1,2−ジイル基、ブタン−1,3−ジイル基、ブタン−1,4−ジイル基、ペンタン−1,4−ジイル基、ペンタン−1,5−ジイル基、ヘキサン−1,5−ジイル基、ヘキサン−1,6−ジイル基等が挙げられる。The “divalent hydrocarbon group” in R 1 , R 2 , R 6 and R 7 is preferably a divalent aliphatic hydrocarbon group. The divalent aliphatic hydrocarbon group may be linear or branched.
The divalent aliphatic hydrocarbon group is preferably an alkanediyl group, specifically, a methane-1,1-diyl group, an ethane-1,1-diyl group, an ethane-1,2-diyl group, Propane-1,1-diyl group, propane-1,2-diyl group, propane-1,3-diyl group, propane-2,2-diyl group, butane-1,2-diyl group, butane-1,3 -Diyl group, butane-1,4-diyl group, pentane-1,4-diyl group, pentane-1,5-diyl group, hexane-1,5-diyl group, hexane-1,6-diyl group, etc. Can be mentioned.
式(1)中のR3としては、−(C=O)O-が好ましい。
式(1)中のR4及びR5、式(2)中のR8、R9及びR10としては、メチル基が好ましい。R 3 in the formula (1) is preferably — (C═O) O 2 — .
As R < 4 > and R < 5 > in Formula (1) and R <8> , R < 9 > and R < 10 > in Formula (2), a methyl group is preferable.
構造単位(A)の好適な具体例としては、下記式(3)で表される構造単位が挙げられる。 Preferable specific examples of the structural unit (A) include a structural unit represented by the following formula (3).
〔式(3)中、
R11は、水素原子又はメチル基を示し、
R12は、−(C=O)−O−*、−(C=O)−NR14−*(R14は、水素原子又はメチル基を示し、*は、式(3)中のR13と結合する位置を示す)又はフェニレン基を示し、
R13は、双性イオン構造を示す。〕[In Formula (3),
R 11 represents a hydrogen atom or a methyl group,
R 12 represents — (C═O) —O— *, — (C═O) —NR 14 — * (R 14 represents a hydrogen atom or a methyl group, and * represents R 13 in formula (3). Or a phenylene group,
R 13 represents a zwitterionic structure. ]
式(3)中、R12としては、非特異吸着抑制の観点から、−(C=O)−O−*、−(C=O)−NR14−*が好ましく、−(C=O)−O−*がより好ましい。
また、R13で示される双性イオン構造は上記双性イオン構造と同様であり、非特異吸着抑制の観点から、第4級アンモニウム塩型カチオン性官能基と、−(C=O)O-、−SO3 -及び−O−(O=P−O-)−O−から選ばれる1価又は2価のアニオン性官能基とを有するものが好ましく、式(1)又は(2)で表されるものが特に好ましい。
また、R14としては、水素原子が好ましい。In formula (3), R 12 is preferably — (C═O) —O— * or — (C═O) —NR 14 — * from the viewpoint of suppressing nonspecific adsorption, and — (C═O). -O- * is more preferred.
Further, zwitterionic structure represented by R 13 are as defined above zwitterion structure, from the viewpoint of inhibiting nonspecific adsorption, and the quaternary ammonium salt type cationic functional group, - (C = O) O - , —SO 3 — and —O— (O═PO — ) — O— are preferred, and those having a monovalent or divalent anionic functional group are represented by the formula (1) or (2). Are particularly preferred.
R 14 is preferably a hydrogen atom.
双性イオン構造を有するモノマーとしては、例えば、[2−((メタ)アクリロイルオキシ)エチル](カルボキシラトメチル)ジメチルアミニウム、[2−((メタ)アクリロイルオキシ)エチル](カルボキシラトエチル)ジメチルアミニウム、[2−((メタ)アクリロイルオキシ)エチル](カルボキシラトプロピル)ジメチルアミニウム、[2−((メタ)アクリロイルオキシ)エチル]ジメチル−(3−スルホメチル)アンモニウムヒドロキシド、[2−((メタ)アクリロイルオキシ)エチル]ジメチル−(3−スルホエチル)アンモニウムヒドロキシド、[2−((メタ)アクリロイルオキシ)エチル]ジメチル−(3−スルホプロピル)アンモニウムヒドロキシド、O−[2−((メタ)アクリロイルオキシ)エトキシ(オキシラト)ホスフィニル]コリン等が挙げられ、これらのうち1種を用いてよく、2種以上を組み合わせて用いてもよい。 Examples of the monomer having a zwitterionic structure include [2-((meth) acryloyloxy) ethyl] (carboxylatomethyl) dimethylaminium, [2-((meth) acryloyloxy) ethyl] (carboxylatoethyl). Dimethylaminium, [2-((meth) acryloyloxy) ethyl] (carboxylatopropyl) dimethylaminium, [2-((meth) acryloyloxy) ethyl] dimethyl- (3-sulfomethyl) ammonium hydroxide, [2 -((Meth) acryloyloxy) ethyl] dimethyl- (3-sulfoethyl) ammonium hydroxide, [2-((meth) acryloyloxy) ethyl] dimethyl- (3-sulfopropyl) ammonium hydroxide, O- [2- ((Meth) acryloyloxy) ethoxy ( Kishirato) phosphinyl] choline and the like, may be using one of these may be used in combination of two or more.
構造単位(A)の含有量は、共重合体(I)中の全構造単位に対して1〜35質量%である。本発明の固相担体は、共重合体(I)中の構造単位(A)が低含量であるため、乳化重合法を利用して簡便に製造することができる。その一方で本発明の固相担体は、上記のように共重合体(I)中の構造単位(A)が低含量であるにも拘らず、非特異吸着が発生しにくく、リガンドを結合して用いた場合に低ノイズで標的物質の検出等を行うことができるという驚くべき性能を有する。
構造単位(A)の含有量は、全構造単位に対して、好ましくは3質量%以上であり、また、非特異吸着抑制や標的物質捕捉性能等の観点から、好ましくは30質量%以下、より好ましくは25質量%以下、更に好ましくは20質量%以下、更に好ましくは15質量%以下、特に好ましくは10質量%以下である。
なお、共重合体(I)中の各構造単位の含有量は、例えば、X線光電子分光分析や元素分析等を利用して測定すればよい。Content of a structural unit (A) is 1-35 mass% with respect to all the structural units in copolymer (I). Since the solid phase carrier of the present invention has a low content of the structural unit (A) in the copolymer (I), it can be easily produced using an emulsion polymerization method. On the other hand, the solid phase carrier of the present invention is less likely to cause non-specific adsorption despite the low content of the structural unit (A) in the copolymer (I) as described above, and binds the ligand. When used, the target substance can be detected with low noise.
The content of the structural unit (A) is preferably 3% by mass or more with respect to all the structural units, and preferably 30% by mass or less from the viewpoint of nonspecific adsorption suppression, target substance capturing performance, and the like. Preferably it is 25 mass% or less, More preferably, it is 20 mass% or less, More preferably, it is 15 mass% or less, Most preferably, it is 10 mass% or less.
The content of each structural unit in the copolymer (I) may be measured using, for example, X-ray photoelectron spectroscopy or elemental analysis.
<構造単位(B)>
共重合体(I)は、リガンドと化学結合可能な官能基を有するモノマーに由来する構造単位を、全構造単位に対して70質量%以下含む。構造単位(B)は、リガンドと化学結合可能な官能基を有するモノマーに由来する構造単位のうち、構造単位(A)以外のものを意味する。
リガンドと化学結合可能な官能基を有するモノマーに由来する構造単位としては、例えば、(メタ)アクリル酸又はその塩に由来する構造単位、リガンドと化学結合可能な官能基を有する(メタ)アクリレート系モノマーに由来する構造単位、リガンドと化学結合可能な官能基を有する(メタ)アクリルアミド系モノマーに由来する構造単位、リガンドと化学結合可能な官能基を有するスチレン系モノマーに由来する構造単位が挙げられ、これらのうち1種を含んでいてもよく、2種以上を含んでいてもよい。
これらの中でも、簡便な手法で製造できる点や非特異吸着抑制の観点等から、(メタ)アクリル酸又はその塩に由来する構造単位、リガンドと化学結合可能な官能基を有する(メタ)アクリレート系モノマーに由来する構造単位、リガンドと化学結合可能な官能基を有する(メタ)アクリルアミド系モノマーに由来する構造単位が好ましく、リガンドと化学結合可能な官能基を有する(メタ)アクリレート系モノマーに由来する構造単位がより好ましい。<Structural unit (B)>
Copolymer (I) contains 70% by mass or less of structural units derived from monomers having a functional group capable of chemically bonding to a ligand, based on the total structural units. The structural unit (B) means a unit other than the structural unit (A) among structural units derived from a monomer having a functional group capable of chemically bonding to a ligand.
Examples of the structural unit derived from a monomer having a functional group capable of chemically bonding to a ligand include, for example, a structural unit derived from (meth) acrylic acid or a salt thereof, and a (meth) acrylate system having a functional group capable of chemically bonding to a ligand. Examples include structural units derived from monomers, structural units derived from (meth) acrylamide monomers having functional groups capable of chemically bonding to ligands, and structural units derived from styrene monomers having functional groups capable of chemically bonding to ligands. One of these may be included, or two or more may be included.
Among these, (meth) acrylates having a functional unit capable of chemically binding to a structural unit derived from (meth) acrylic acid or a salt thereof, from the viewpoint of being able to be produced by a simple method and from the viewpoint of suppressing nonspecific adsorption A structural unit derived from a monomer or a structural unit derived from a (meth) acrylamide monomer having a functional group capable of chemically bonding to a ligand is preferred, and derived from a (meth) acrylate monomer having a functional group capable of chemically bonding to a ligand. A structural unit is more preferable.
また、リガンドと化学結合可能な官能基としては、カルボキシ基、トシル基、アミノ基、エポキシ基、アジド基が挙げられる。これらの中でも、標的物質捕捉性能の観点や、リガンドとしてタンパク質や核酸等の生体分子を使用する場合にリガンドが元来有している官能基を使用して固相担体と結合できる点から、カルボキシ基、トシル基、アミノ基、エポキシ基が好ましく、カルボキシ基がより好ましい。 Examples of the functional group that can be chemically bonded to the ligand include a carboxy group, a tosyl group, an amino group, an epoxy group, and an azide group. Among these, from the viewpoint of target substance capturing performance, and when using biomolecules such as proteins and nucleic acids as ligands, it is possible to bind to a solid phase carrier using a functional group that the ligand originally has. Group, tosyl group, amino group and epoxy group are preferred, and carboxy group is more preferred.
また、リガンドと化学結合可能な官能基の含有量は、非特異吸着抑制や標的物質捕捉性能等の観点から、固相担体の固形分1gあたり、好ましくは1μmol以上、より好ましくは10μmol以上、更に好ましくは25μmol以上、特に好ましくは50μmol以上であり、また、非特異吸着抑制や標的物質捕捉性能等の観点から、好ましくは800μmol以下、より好ましくは650μmol以下、更に好ましくは500μmol以下である。
リガンドと化学結合可能な官能基の含有量は、例えば、リガンドと化学結合可能な官能基がカルボキシ基の場合、電気伝導度測定法等により測定可能であり、具体的には、後述する実施例に記載の方法に従い測定できる。また、リガンドと化学結合可能な官能基がトシル基の場合は、トシル基の紫外可視光吸収を測定するなどして求めることができ、リガンドと化学結合可能な官能基がアミノ基の場合は、アミノ基にN−スクシイミジル−3−(2−ピリジルジチオ)プロピオナートを反応させた後、還元し、遊離のチオピリジル基の吸光度を測定するなどして求めることができる。Further, the content of the functional group capable of chemically binding to the ligand is preferably 1 μmol or more, more preferably 10 μmol or more, more preferably 10 μmol or more, per 1 g of the solid content of the solid phase carrier, from the viewpoint of non-specific adsorption suppression, target substance capture performance, etc. The amount is preferably 25 μmol or more, particularly preferably 50 μmol or more, and is preferably 800 μmol or less, more preferably 650 μmol or less, and still more preferably 500 μmol or less, from the viewpoint of nonspecific adsorption suppression, target substance capture performance, and the like.
The content of the functional group that can be chemically bonded to the ligand can be measured by, for example, an electrical conductivity measurement method when the functional group that can be chemically bonded to the ligand is a carboxy group. According to the method described in 1. In addition, when the functional group that can be chemically bonded to the ligand is a tosyl group, it can be determined by measuring the ultraviolet-visible light absorption of the tosyl group, and when the functional group that can be chemically bonded to the ligand is an amino group, It can be determined by reacting N-succinimidyl-3- (2-pyridyldithio) propionate with an amino group, followed by reduction and measuring the absorbance of the free thiopyridyl group.
構造単位(B)の好適な具体例としては、下記式(4)で表される構造単位が挙げられる。 Preferable specific examples of the structural unit (B) include a structural unit represented by the following formula (4).
〔式(4)中、
R15は、水素原子又はメチル基を示し、
R16は、−(C=O)−O−*、−(C=O)−NR18−*(R18は、水素原子又はメチル基を示し、*は、式(4)中のR17と結合する位置を示す)又はフェニレン基を示し、
R16が−(C=O)−O−*である場合、R17は、水素原子、又はリガンドと化学結合可能な官能基を有する有機基を示し、R16が−(C=O)−NR18−*又はフェニレン基である場合、R17は、リガンドと化学結合可能な官能基を有する有機基を示す。〕[In Formula (4),
R 15 represents a hydrogen atom or a methyl group,
R 16 represents — (C═O) —O— *, — (C═O) —NR 18 — * (R 18 represents a hydrogen atom or a methyl group, and * represents R 17 in formula (4). Or a phenylene group,
When R 16 is — (C═O) —O— *, R 17 represents a hydrogen atom or an organic group having a functional group capable of chemically bonding to a ligand, and R 16 represents — (C═O) —. NR 18 - If a * or a phenylene group, R 17 represents an organic group having a ligand capable of chemically bonding functional groups. ]
式(5)中、R16としては、非特異吸着抑制の観点から、−(C=O)−O−*、−(C=O)−NR18−*が好ましく、−(C=O)−O−*がより好ましい。R18としては、水素原子が好ましい。In the formula (5), R 16 is preferably — (C═O) —O— * or — (C═O) —NR 18 — * from the viewpoint of suppressing nonspecific adsorption, and — (C═O). -O- * is more preferred. R 18 is preferably a hydrogen atom.
また、R17としては、簡便な手法で製造できる点や非特異吸着抑制の観点等から、リガンドと化学結合可能な官能基を有する有機基が好ましい。リガンドと化学結合可能な官能基を有する有機基としては、下記式(5)で表される有機基が好ましい。なお、R17、Yにおけるリガンドと化学結合可能な官能基は、上記リガンドと化学結合可能な官能基と同様であり、カルボキシ基、トシル基、アミノ基、エポキシ基が好ましく、カルボキシ基がより好ましい。R 17 is preferably an organic group having a functional group that can be chemically bonded to a ligand from the viewpoint of being able to be produced by a simple method and from the viewpoint of suppressing nonspecific adsorption. As the organic group having a functional group capable of chemically bonding to the ligand, an organic group represented by the following formula (5) is preferable. The functional group capable of being chemically bonded to the ligand in R 17 and Y is the same as the functional group capable of being chemically bonded to the ligand, preferably a carboxy group, a tosyl group, an amino group, or an epoxy group, and more preferably a carboxy group. .
〔式(5)中、
R19は、2価の有機基を示し、
Yは、リガンドと化学結合可能な官能基を示す。〕[In Formula (5),
R 19 represents a divalent organic group,
Y represents a functional group that can be chemically bonded to a ligand. ]
R19で示される2価の有機基としては、2価の炭化水素基、炭素数2以上の2価の炭化水素基の炭素−炭素原子間にエーテル結合、イミノ基、アミド結合及びエステル結合から選ばれる1種以上を有する基が挙げられ、炭素数2以上の2価の炭化水素基の炭素−炭素原子間にエーテル結合、イミノ基、アミド結合及びエステル結合から選ばれる1種以上を有する基が好ましい。The divalent organic group represented by R 19 includes a divalent hydrocarbon group, an ether bond, an imino group, an amide bond and an ester bond between carbon-carbon atoms of a divalent hydrocarbon group having 2 or more carbon atoms. Groups having one or more selected groups, and groups having at least one selected from an ether bond, an imino group, an amide bond and an ester bond between carbon-carbon atoms of a divalent hydrocarbon group having 2 or more carbon atoms. Is preferred.
2価の有機基が2価の炭化水素基である場合、その炭素数としては、1〜20が好ましく、1〜10がより好ましく、1〜8が更に好ましく、1〜6が特に好ましい。
また、2価の有機基が2価の炭化水素基である場合において、当該2価の炭化水素基は、2価の脂肪族炭化水素基、2価の脂環式炭化水素基及び2価の芳香族炭化水素基を含む概念であるが、2価の脂肪族炭化水素基が好ましい。当該2価の脂肪族炭化水素基は直鎖状でも分岐鎖状でもよい。
上記2価の脂肪族炭化水素基としては、アルカンジイル基が好ましく、具体的には、メタン−1,1−ジイル基、エタン−1,1−ジイル基、エタン−1,2−ジイル基、プロパン−1,1−ジイル基、プロパン−1,2−ジイル基、プロパン−1,3−ジイル基、プロパン−2,2−ジイル基、ブタン−1,2−ジイル基、ブタン−1,3−ジイル基、ブタン−1,4−ジイル基、ペンタン−1,4−ジイル基、ペンタン−1,5−ジイル基、ヘキサン−1,5−ジイル基、ヘキサン−1,6−ジイル基等が挙げられる。When the divalent organic group is a divalent hydrocarbon group, the carbon number is preferably 1-20, more preferably 1-10, still more preferably 1-8, and particularly preferably 1-6.
In the case where the divalent organic group is a divalent hydrocarbon group, the divalent hydrocarbon group includes a divalent aliphatic hydrocarbon group, a divalent alicyclic hydrocarbon group, and a divalent hydrocarbon group. The concept includes an aromatic hydrocarbon group, but a divalent aliphatic hydrocarbon group is preferable. The divalent aliphatic hydrocarbon group may be linear or branched.
The divalent aliphatic hydrocarbon group is preferably an alkanediyl group, specifically, a methane-1,1-diyl group, an ethane-1,1-diyl group, an ethane-1,2-diyl group, Propane-1,1-diyl group, propane-1,2-diyl group, propane-1,3-diyl group, propane-2,2-diyl group, butane-1,2-diyl group, butane-1,3 -Diyl group, butane-1,4-diyl group, pentane-1,4-diyl group, pentane-1,5-diyl group, hexane-1,5-diyl group, hexane-1,6-diyl group, etc. Can be mentioned.
一方、2価の有機基が炭素数2以上の2価の炭化水素基の炭素−炭素原子間にエーテル結合、イミノ基、アミド結合及びエステル結合から選ばれる1種以上を有する基である場合、その合計炭素数としては、2〜20が好ましく、2〜16がより好ましく、2〜12が更に好ましく、2〜8が特に好ましい。
また、炭素数2以上の2価の炭化水素基の炭素−炭素原子間にエーテル結合、イミノ基、アミド結合及びエステル結合から選ばれる1種以上を有する基としては、下記式(6)で表される2価の基が好ましい。On the other hand, when the divalent organic group is a group having one or more selected from an ether bond, an imino group, an amide bond and an ester bond between carbon-carbon atoms of a divalent hydrocarbon group having 2 or more carbon atoms, As the total carbon number, 2-20 are preferable, 2-16 are more preferable, 2-12 are still more preferable, and 2-8 are especially preferable.
In addition, the group having one or more selected from an ether bond, an imino group, an amide bond and an ester bond between carbon-carbon atoms of a divalent hydrocarbon group having 2 or more carbon atoms is represented by the following formula (6). Preferred is a divalent group.
〔式(6)中、
R20及びR21は、それぞれ独立して、2価の炭化水素基を示し、
Xは、エーテル結合、イミノ基、アミド結合又はエステル結合を示し、
*は、式(5)中のYとの結合位置を示す。〕[In Formula (6),
R 20 and R 21 each independently represent a divalent hydrocarbon group,
X represents an ether bond, an imino group, an amide bond or an ester bond,
* Indicates a bonding position with Y in the formula (5). ]
Xとしては、エステル結合が好ましい。
R20及びR21で示される2価の炭化水素基は、2価の脂肪族炭化水素基、2価の脂環式炭化水素基及び2価の芳香族炭化水素基を含む概念である。
2価の脂肪族炭化水素基の炭素数としては、1〜10が好ましく、1〜8がより好ましく、1〜6が特に好ましい。なお、2価の脂肪族炭化水素基は直鎖状でも分岐鎖状でもよい。
上記2価の脂肪族炭化水素基としては、アルカンジイル基が好ましく、具体的には、メタン−1,1−ジイル基、エタン−1,1−ジイル基、エタン−1,2−ジイル基、プロパン−1,1−ジイル基、プロパン−1,2−ジイル基、プロパン−1,3−ジイル基、プロパン−2,2−ジイル基、ブタン−1,2−ジイル基、ブタン−1,3−ジイル基、ブタン−1,4−ジイル基、ペンタン−1,4−ジイル基、ペンタン−1,5−ジイル基、ヘキサン−1,5−ジイル基、ヘキサン−1,6−ジイル基等が挙げられる。
2価の脂環式炭化水素基の炭素数としては、5〜10が好ましく、5〜7がより好ましい。2価の脂環式炭化水素基としては、シクロアルカンジイル基が好ましく、具体的には、シクロヘキサンジイル基、シクロヘプタンジイル基等が挙げられる。
2価の芳香族炭化水素基の炭素数としては、6〜18が好ましく、6〜12がより好ましい。2価の芳香族炭化水素基としては、アリーレン基が好ましく、具体的には、フェニレン基、ナフチレン基等が挙げられる。X is preferably an ester bond.
The divalent hydrocarbon group represented by R 20 and R 21 is a concept including a divalent aliphatic hydrocarbon group, a divalent alicyclic hydrocarbon group, and a divalent aromatic hydrocarbon group.
As carbon number of a bivalent aliphatic hydrocarbon group, 1-10 are preferable, 1-8 are more preferable, and 1-6 are especially preferable. The divalent aliphatic hydrocarbon group may be linear or branched.
The divalent aliphatic hydrocarbon group is preferably an alkanediyl group, specifically, a methane-1,1-diyl group, an ethane-1,1-diyl group, an ethane-1,2-diyl group, Propane-1,1-diyl group, propane-1,2-diyl group, propane-1,3-diyl group, propane-2,2-diyl group, butane-1,2-diyl group, butane-1,3 -Diyl group, butane-1,4-diyl group, pentane-1,4-diyl group, pentane-1,5-diyl group, hexane-1,5-diyl group, hexane-1,6-diyl group, etc. Can be mentioned.
As carbon number of a bivalent alicyclic hydrocarbon group, 5-10 are preferable and 5-7 are more preferable. The divalent alicyclic hydrocarbon group is preferably a cycloalkanediyl group, and specific examples include a cyclohexanediyl group and a cycloheptanediyl group.
As carbon number of a bivalent aromatic hydrocarbon group, 6-18 are preferable and 6-12 are more preferable. The divalent aromatic hydrocarbon group is preferably an arylene group, and specific examples include a phenylene group and a naphthylene group.
また、R20とR21との組み合わせとしては、R20が2価の脂肪族炭化水素基であり、R21が2価の脂肪族炭化水素基、2価の脂環式炭化水素基又は2価の芳香族炭化水素基である組み合わせが好ましく、R20が2価の脂肪族炭化水素基であり、R21が2価の脂肪族炭化水素基である組み合わせがより好ましい。As a combination of R 20 and R 21 , R 20 is a divalent aliphatic hydrocarbon group, and R 21 is a divalent aliphatic hydrocarbon group, a divalent alicyclic hydrocarbon group, or 2 A combination that is a divalent aromatic hydrocarbon group is preferable, and a combination that R 20 is a divalent aliphatic hydrocarbon group and R 21 is a divalent aliphatic hydrocarbon group is more preferable.
リガンドと化学結合可能な官能基を有するモノマーとしては、例えば、コハク酸水素1−((メタ)アクリロイルオキシ)エチル、フタル酸1−(1−(メタ)アクリロイルオキシエチル)、1,2−シクロヘキサンジカルボン酸水素1−[1−((メタ)アクリロイルオキシ)エチル]、コハク酸水素1−((メタ)アクリロイルオキシ)プロピル、1,2−シクロヘキサンジカルボン酸水素1−[1−((メタ)アクリロイルオキシ)プロピル]、コハク酸1−(2−(メタ)アクリロイルオキシエチル)、フタル酸1−(2−(メタ)アクリロイルオキシエチル)、ヘキサヒドロフタル酸水素1−(2−(メタ)アクリロイルオキシエチル)、コハク酸水素2−((メタ)アクリロイルオキシ)プロピル、フタル酸水素1−(2−(メタ)アクリロイルオキシプロピル)、ヘキサヒドロフタル酸水素1−(2−(メタ)アクリロイルオキシプロピル)、コハク酸水素3−((メタ)アクリロイルオキシ)プロピル、フタル酸水素1−(3−(メタ)アクリロイルオキシプロピル)、1,2−シクロヘキサンジカルボン酸水素1−[3−((メタ)アクリロイルオキシ)プロピル]等が挙げられ、これらのうち1種を用いてよく、2種以上を組み合わせて用いてもよい。 Examples of the monomer having a functional group capable of chemically bonding with a ligand include hydrogen 1-((meth) acryloyloxy) ethyl succinate, 1- (1- (meth) acryloyloxyethyl) phthalate, and 1,2-cyclohexane. Hydrogen dicarboxylate 1- [1-((meth) acryloyloxy) ethyl], hydrogen 1-((meth) acryloyloxy) propyl succinate, hydrogen 1- [1-((meth) acryloyl) 1,2-cyclohexanedicarboxylate Oxy) propyl], succinic acid 1- (2- (meth) acryloyloxyethyl), phthalic acid 1- (2- (meth) acryloyloxyethyl), hydrogen hexahydrophthalate 1- (2- (meth) acryloyloxy) Ethyl), hydrogen succinate 2-((meth) acryloyloxy) propyl, hydrogen phthalate 1- (2- (methyl ) Acryloyloxypropyl), hydrogen hexahydrophthalate 1- (2- (meth) acryloyloxypropyl), hydrogen succinate 3-((meth) acryloyloxy) propyl, hydrogen phthalate 1- (3- (meth) acryloyl) Oxypropyl), hydrogen 1,2-cyclohexanedicarboxylate 1- [3-((meth) acryloyloxy) propyl] and the like, and one of these may be used, or two or more may be used in combination. Good.
構造単位(B)の含有量は、共重合体中の全構造単位に対して70質量%以下である。斯かる構成により、非特異吸着が発生しにくくなり、また、標的物質捕捉性能が向上する。
構造単位(B)の含有量は、全構造単位に対して、非特異吸着抑制や標的物質捕捉性能等の観点から、好ましくは1質量%以上、より好ましくは10質量%以上、特に好ましくは20質量%以上であり、また、非特異吸着抑制や標的物質捕捉性能等の観点から、好ましくは60質量%以下、より好ましくは50質量%以下、特に好ましくは40質量%以下である。Content of a structural unit (B) is 70 mass% or less with respect to all the structural units in a copolymer. With such a configuration, nonspecific adsorption is less likely to occur, and the target substance capturing performance is improved.
The content of the structural unit (B) is preferably 1% by mass or more, more preferably 10% by mass or more, and particularly preferably 20% from the viewpoints of nonspecific adsorption suppression, target substance capturing performance, and the like with respect to all structural units. In addition, from the viewpoint of nonspecific adsorption suppression and target substance capturing performance, it is preferably 60% by mass or less, more preferably 50% by mass or less, and particularly preferably 40% by mass or less.
また、構造単位(A)と構造単位(B)の含有量の質量比〔(A):(B)〕としては、非特異吸着抑制や標的物質捕捉性能等の観点から、5:95〜60:40が好ましく、10:90〜50:50がより好ましく、15:85〜40:60が更に好ましく、17.5:82.5〜35:65が更に好ましく、17.5:82.5〜30:70が更に好ましく、17.5:82.5〜25:75が特に好ましい。 Moreover, as mass ratio [(A) :( B)] of content of a structural unit (A) and a structural unit (B), it is 5: 95-60 from viewpoints of nonspecific adsorption | suction suppression, target substance capture | acquisition performance, etc. : 40 is preferable, 10:90 to 50:50 is more preferable, 15:85 to 40:60 is more preferable, 17.5: 82.5 to 35:65 is still more preferable, and 17.5: 82.5 to 30:70 is more preferable, and 17.5: 82.5 to 25:75 is particularly preferable.
<構造単位(C)>
共重合体(I)は、上記構造単位(A)及び(B)以外に、リガンドと化学結合可能な官能基を有さない水難溶性モノマーに由来する構造単位を含む。斯かる構成により、非特異吸着が発生しにくくなり、また、標的物質捕捉性能が向上する。
なお、本明細書において、水難溶性モノマーとは、水100gに対して10g以下の溶解性をもつモノマーを意味する。<Structural unit (C)>
Copolymer (I) contains, in addition to the structural units (A) and (B), a structural unit derived from a poorly water-soluble monomer having no functional group capable of chemically bonding to a ligand. With such a configuration, nonspecific adsorption is less likely to occur, and the target substance capturing performance is improved.
In the present specification, the poorly water-soluble monomer means a monomer having a solubility of 10 g or less with respect to 100 g of water.
リガンドと化学結合可能な官能基を有さない水難溶性モノマーに由来する構造単位としては、例えば、リガンドと化学結合可能な官能基を有さない水難溶性(メタ)アクリレート系モノマーに由来する構造単位、リガンドと化学結合可能な官能基を有さない水難溶性(メタ)アクリルアミド系モノマーに由来する構造単位、リガンドと化学結合可能な官能基を有さない水難溶性スチレン系モノマーに由来する構造単位が挙げられ、これらのうち1種を含んでいてもよく、2種以上を含んでいてもよい。また、これら構造単位を誘導する水難溶性モノマーは、単官能性モノマーでも多官能性モノマーでもよい。
これらの中でも、非特異吸着抑制の観点等から、リガンドと化学結合可能な官能基を有さない水難溶性(メタ)アクリレート系モノマーに由来する構造単位、リガンドと化学結合可能な官能基を有さない水難溶性(メタ)アクリルアミド系モノマーに由来する構造単位が好ましく、リガンドと化学結合可能な官能基を有さない水難溶性(メタ)アクリレート系モノマーに由来する構造単位がより好ましい。Examples of the structural unit derived from a poorly water-soluble monomer that does not have a functional group that can be chemically bonded to a ligand include, for example, a structural unit derived from a poorly water-soluble (meth) acrylate monomer that does not have a functional group that can be chemically bonded to a ligand. A structural unit derived from a poorly water-soluble (meth) acrylamide monomer that does not have a functional group capable of chemically binding to a ligand, and a structural unit derived from a poorly water-soluble styrene monomer that does not have a functional group capable of chemically binding to a ligand. 1 type may be included among these, and 2 or more types may be included. Further, the poorly water-soluble monomer for deriving these structural units may be a monofunctional monomer or a polyfunctional monomer.
Among these, from the viewpoint of suppressing non-specific adsorption, etc., it has a structural unit derived from a poorly water-soluble (meth) acrylate monomer that does not have a functional group that can be chemically bonded to the ligand, and has a functional group that can be chemically bonded to the ligand. A structural unit derived from a poorly water-soluble (meth) acrylamide monomer is preferred, and a structural unit derived from a poorly water-soluble (meth) acrylate monomer having no functional group capable of chemically bonding to a ligand is more preferred.
構造単位(C)としては、以下の構造単位(C−1)〜(C−3)が好ましい。なお、共重合体(I)は、これらのうち1種を含んでいてもよく、2種以上を含んでいてもよい。 As the structural unit (C), the following structural units (C-1) to (C-3) are preferable. In addition, copolymer (I) may contain 1 type in these, and may contain 2 or more types.
(C−1)重合させてホモポリマーとし自由水を共存させた場合に中間水を保持するモノアクリレートモノマー又は該モノアクリレートモノマーと側鎖の構造が同一のモノメタクリレートモノマーに由来する構造単位 (C-1) Monoacrylate monomer that retains intermediate water when polymerized as a homopolymer and coexisting with free water, or a structural unit derived from a monomethacrylate monomer having the same side chain structure as the monoacrylate monomer
(C−2)下記式(7)で表されるモノ(メタ)アクリレートモノマーに由来する構造単位 (C-2) Structural unit derived from a mono (meth) acrylate monomer represented by the following formula (7)
〔式(7)中、
R22は、水素原子又はメチル基を示し、
R23は、炭化水素基を示す。〕[In Formula (7),
R 22 represents a hydrogen atom or a methyl group,
R 23 represents a hydrocarbon group. ]
(C−3)多官能性モノマーに由来する構造単位 (C-3) Structural unit derived from polyfunctional monomer
(構造単位(C−1))
構造単位(C−1)は、重合させてホモポリマーとし自由水を共存させた場合に中間水を保持するモノアクリレートモノマー又は該モノアクリレートモノマーと側鎖の構造が同一のモノメタクリレートモノマーに由来する構造単位である。(Structural unit (C-1))
The structural unit (C-1) is derived from a monoacrylate monomer which is polymerized to form a homopolymer and retains intermediate water when free water coexists, or a monomethacrylate monomer having the same side chain structure as the monoacrylate monomer. A structural unit.
ここで、自由水を共存させた場合に中間水を保持するホモポリマーとは、示差走査熱量計(DSC)による示差走査熱量分析によって得られるDSC曲線において、昇温過程で−10℃未満に水の結晶化による発熱ピークが観測されるホモポリマーをいう。
また、自由水とは、示差走査熱量分析によって得られるDSC曲線において、昇温過程で0℃付近の融点(吸熱ピーク)として観測される水をいう。
また、中間水とは、示差走査熱量分析によって得られるDSC曲線において、昇温過程で、−10℃未満で結晶化による発熱ピークとして観測される水をいう。
また、昇温過程とは、示差走査熱量分析において、−100℃以下まで冷却したのちの昇温過程をいう。Here, the homopolymer that retains intermediate water when free water coexists means that the water temperature is less than −10 ° C. in the DSC curve obtained by differential scanning calorimetry using a differential scanning calorimeter (DSC) in the temperature rising process. A homopolymer in which an exothermic peak due to crystallization is observed.
Free water refers to water that is observed as a melting point (endothermic peak) near 0 ° C. in the DSC curve obtained by differential scanning calorimetry in the temperature rising process.
The intermediate water refers to water that is observed as an exothermic peak due to crystallization at a temperature of less than −10 ° C. in the DSC curve obtained by differential scanning calorimetry in the temperature rising process.
The temperature raising process refers to a temperature raising process after cooling to −100 ° C. or lower in differential scanning calorimetry.
構造単位(C−1)としては、下記式(8)又は(9)で表されるモノマーに由来する構造単位が好ましく、下記式(9)で表されるモノマーに由来する構造単位がより好ましい。 As the structural unit (C-1), a structural unit derived from a monomer represented by the following formula (8) or (9) is preferable, and a structural unit derived from a monomer represented by the following formula (9) is more preferable. .
〔式(8)中、
R24は、水素原子又はメチル基を示し、
R25は、炭素数1〜3のアルカンジイル基を示し、
R26は、炭素数1〜3のアルキル基を示し、
nは、1〜5の整数を示す。〕[In Formula (8),
R 24 represents a hydrogen atom or a methyl group,
R 25 represents an alkanediyl group having 1 to 3 carbon atoms;
R 26 represents an alkyl group having 1 to 3 carbon atoms,
n shows the integer of 1-5. ]
〔式(9)中、
R27は、水素原子又はメチル基を示し、
mは、1又は2を示す。〕[In Formula (9),
R 27 represents a hydrogen atom or a methyl group,
m represents 1 or 2. ]
式(8)中、R25で示されるアルカンジイル基の炭素数としては、2又は3が好ましく、2がより好ましい。また、アルカンジイル基は直鎖状でも分岐鎖状でもよく、具体例としては、エタン−1,1−ジイル基、エタン−1,2−ジイル基、プロパン−1,1−ジイル基、プロパン−1,2−ジイル基、プロパン−1,3−ジイル基、プロパン−2,2−ジイル基等が挙げられる。
R26で示されるアルキル基の炭素数としては、1又は2が好ましい。また、アルキル基は直鎖状でも分岐鎖状でもよく、具体例としては、メチル基、エチル基、n−プロピル基、イソプロピル基等が挙げられる。
nは、1〜5の整数を示すが、1〜3の整数が好ましい。
式(9)中、mは、1又は2を示すが、1が好ましい。In formula (8), the carbon number of the alkanediyl group represented by R 25 is preferably 2 or 3, and more preferably 2. The alkanediyl group may be linear or branched. Specific examples thereof include ethane-1,1-diyl group, ethane-1,2-diyl group, propane-1,1-diyl group, propane- 1,2-diyl group, propane-1,3-diyl group, propane-2,2-diyl group and the like can be mentioned.
The number of carbon atoms of the alkyl group represented by R 26 is preferably 1 or 2. The alkyl group may be linear or branched, and specific examples include a methyl group, an ethyl group, an n-propyl group, and an isopropyl group.
n represents an integer of 1 to 5, and an integer of 1 to 3 is preferable.
In formula (9), m represents 1 or 2, but 1 is preferable.
構造単位(C−1)を誘導するモノマーとしては、メトキシエチルアクリレート、メトキシエチルメタクリレート、テトラヒドロフルフリルアクリレート、テトラヒドロフルフリルメタクリレート、ジ(エチレングリコール)モノメチルエーテルアクリレート、ジ(エチレングリコール)モノメチルエーテルメタクリレート、ジ(エチレングリコール)モノエチルエーテルアクリレート、ジ(エチレングリコール)モノエチルエーテルメタクリレート、トリ(エチレングリコール)モノメチルエーテルアクリレート、トリ(エチレングリコール)モノメチルエーテルメタクリレート、トリ(エチレングリコール)モノエチルエーテルアクリレート、トリ(エチレングリコール)モノエチルエーテルメタクリレート等が挙げられ、これらのうち1種を用いてよく、2種以上を組み合わせて用いてもよい。 As the monomer for deriving the structural unit (C-1), methoxyethyl acrylate, methoxyethyl methacrylate, tetrahydrofurfuryl acrylate, tetrahydrofurfuryl methacrylate, di (ethylene glycol) monomethyl ether acrylate, di (ethylene glycol) monomethyl ether methacrylate, Di (ethylene glycol) monoethyl ether acrylate, di (ethylene glycol) monoethyl ether methacrylate, tri (ethylene glycol) monomethyl ether acrylate, tri (ethylene glycol) monomethyl ether methacrylate, tri (ethylene glycol) monoethyl ether acrylate, tri ( Ethylene glycol) monoethyl ether methacrylate, etc. Well with seeds, it may be used in combination of two or more.
(構造単位(C−2))
構造単位(C−2)は、下記式(7)で表されるモノ(メタ)アクリレートモノマーに由来する構造単位である。(Structural unit (C-2))
The structural unit (C-2) is a structural unit derived from a mono (meth) acrylate monomer represented by the following formula (7).
〔式(7)中、
R22は、水素原子又はメチル基を示し、
R23は、炭化水素基を示す。〕[In Formula (7),
R 22 represents a hydrogen atom or a methyl group,
R 23 represents a hydrocarbon group. ]
R23で示される炭化水素基は、脂肪族炭化水素基、脂環式炭化水素基及び芳香族炭化水素基を包含する概念である。
R23における脂肪族炭化水素基の炭素数としては、1〜20が好ましく、1〜12がより好ましく、1〜8が更に好ましい。なお、脂肪族炭化水素基は、直鎖状でも分岐鎖状でもよい。脂肪族炭化水素基としては、アルキル基が好ましく、具体的には、メチル基、エチル基、n−プロピル基、イソプロピル基、n−ブチル基、イソブチル基、sec−ブチル基、tert−ブチル基、ペンチル基、ヘキシル基、ヘプチル基、オクチル基等が挙げられる。
R23における脂環式炭化水素基の炭素数としては、6〜12が好ましく、6〜10がより好ましい。脂環式炭化水素基は、単環の脂環式炭化水素基と橋かけ環炭化水素基に大別される。単環の脂環式炭化水素基としては、シクロプロピル基、シクロヘキシル基等のシクロアルキル基が挙げられる。また、橋かけ環炭化水素基としては、イソボルニル基等が挙げられる。
R23における芳香族炭化水素基の炭素数としては、6〜12が好ましい。芳香族炭化水素基としては、フェニル基等のアリール基が挙げられる。The hydrocarbon group represented by R 23 is a concept including an aliphatic hydrocarbon group, an alicyclic hydrocarbon group, and an aromatic hydrocarbon group.
The number of carbon atoms of the aliphatic hydrocarbon group for R 23, preferably from 1 to 20, more preferably 1 to 12, 1 to 8 is more preferable. The aliphatic hydrocarbon group may be linear or branched. As the aliphatic hydrocarbon group, an alkyl group is preferable, and specifically, a methyl group, an ethyl group, an n-propyl group, an isopropyl group, an n-butyl group, an isobutyl group, a sec-butyl group, a tert-butyl group, A pentyl group, a hexyl group, a heptyl group, an octyl group, etc. are mentioned.
The number of carbon atoms of the alicyclic hydrocarbon group in R 23, 6 to 12 is preferable, 6 to 10 is more preferable. The alicyclic hydrocarbon group is roughly classified into a monocyclic alicyclic hydrocarbon group and a bridged ring hydrocarbon group. Examples of the monocyclic alicyclic hydrocarbon group include cycloalkyl groups such as a cyclopropyl group and a cyclohexyl group. Examples of the bridged ring hydrocarbon group include an isobornyl group.
The number of carbon atoms of the aromatic hydrocarbon group for R 23, 6 to 12 is preferable. Examples of the aromatic hydrocarbon group include aryl groups such as a phenyl group.
これら炭化水素基の中でも、R23としては、脂環式炭化水素基が好ましく、シクロアルキル基がより好ましい。Among these hydrocarbon groups, R 23 is preferably an alicyclic hydrocarbon group, and more preferably a cycloalkyl group.
構造単位(C−2)を誘導するモノマーとしては、メチル(メタ)アクリレート、エチル(メタ)アクリレート、ステアリル(メタ)アクリレート、シクロヘキシル(メタ)アクリレート、イソボルニル(メタ)アクリレート等が挙げられ、これらのうち1種を用いてよく、2種以上を組み合わせて用いてもよい。 Examples of the monomer for deriving the structural unit (C-2) include methyl (meth) acrylate, ethyl (meth) acrylate, stearyl (meth) acrylate, cyclohexyl (meth) acrylate, isobornyl (meth) acrylate, and the like. Of these, one type may be used, or two or more types may be used in combination.
(構造単位(C−3))
構造単位(C−3)は、多官能性モノマーに由来する構造単位である。例えば、多官能性(メタ)アクリレート系モノマー;ジビニルベンゼン等の多官能性芳香族ビニル系モノマー;ブタジエン、イソプレン等の共役ジオレフィン等が挙げられる。これらの中でも、多官能性(メタ)アクリレート系モノマーが好ましい。多官能性(メタ)アクリレート系モノマーとしては、エチレングリコールジ(メタ)アクリレート、アリル(メタ)アクリレート等の二官能性(メタ)アクリレート系モノマー;トリメチロールプロパントリ(メタ)アクリレート等の三官能性(メタ)アクリレート系モノマー;ジペンタエリスリトールヘキサ(メタ)メタクリレート等の六官能性(メタ)アクリレート系モノマー等が挙げられる。(Structural unit (C-3))
The structural unit (C-3) is a structural unit derived from a polyfunctional monomer. Examples include polyfunctional (meth) acrylate monomers; polyfunctional aromatic vinyl monomers such as divinylbenzene; conjugated diolefins such as butadiene and isoprene. Among these, a polyfunctional (meth) acrylate monomer is preferable. Multifunctional (meth) acrylate monomers include bifunctional (meth) acrylate monomers such as ethylene glycol di (meth) acrylate and allyl (meth) acrylate; trifunctionality such as trimethylolpropane tri (meth) acrylate (Meth) acrylate monomers; hexafunctional (meth) acrylate monomers such as dipentaerythritol hexa (meth) methacrylate and the like.
また、構造単位(C)としては、非特異吸着抑制や標的物質捕捉性能等の観点から、構造単位(C−1)を少なくとも含むもの、構造単位(C−3)を少なくとも含むものが好ましく、構造単位(C−1)を少なくとも含むものがより好ましく、構造単位(C−1)及び(C−3)を少なくとも含むものが特に好ましい。 Moreover, as the structural unit (C), from the viewpoint of non-specific adsorption suppression and target substance capturing performance, those containing at least the structural unit (C-1) and those containing at least the structural unit (C-3) are preferable. Those containing at least the structural unit (C-1) are more preferred, and those containing at least the structural units (C-1) and (C-3) are particularly preferred.
構造単位(C)の合計含有量は、全構造単位に対して、非特異吸着抑制や標的物質捕捉性能等の観点から、好ましくは10質量%以上、より好ましくは30質量%以上、更に好ましくは40質量%以上、更に好ましくは50質量%以上、特に好ましくは55質量%以上であり、また、非特異吸着抑制や標的物質捕捉性能等の観点から、好ましくは90質量%以下、より好ましくは80質量%以下、特に好ましくは70質量%以下である。 The total content of the structural unit (C) is preferably 10% by mass or more, more preferably 30% by mass or more, and still more preferably from the viewpoints of non-specific adsorption suppression and target substance capturing performance, etc. It is 40% by mass or more, more preferably 50% by mass or more, particularly preferably 55% by mass or more, and preferably 90% by mass or less, more preferably 80% from the viewpoint of non-specific adsorption suppression and target substance capturing performance. It is at most 70% by mass, particularly preferably at most 70% by mass.
また、構造単位(A)と構造単位(C)の含有量の質量比〔(A):(C)〕としては、非特異吸着抑制や標的物質捕捉性能等の観点から、1:99〜60:40が好ましく、5:95〜50:50がより好ましく、10:90〜40:60が更に好ましく、10:90〜30:70が更に好ましく、10:90〜20:80が特に好ましい。
また、構造単位(B)と構造単位(C)の含有量の質量比〔(B):(C)〕としては、非特異吸着抑制や標的物質捕捉性能等の観点から、1:99〜99:1が好ましく、10:90〜60:40がより好ましく、20:80〜45:55が更に好ましく、20:80〜40:60が特に好ましい。Moreover, as mass ratio [(A) :( C)] of content of a structural unit (A) and a structural unit (C), it is 1: 99-60 from viewpoints of nonspecific adsorption | suction suppression, target substance capture | acquisition performance, etc. : 40 is preferable, 5:95 to 50:50 is more preferable, 10:90 to 40:60 is more preferable, 10:90 to 30:70 is still more preferable, and 10:90 to 20:80 is particularly preferable.
Moreover, as mass ratio [(B) :( C)] of content of a structural unit (B) and a structural unit (C), it is 1: 99-99 from viewpoints of nonspecific adsorption | suction suppression, target substance capture | acquisition performance, etc. : 1 is preferable, 10:90 to 60:40 is more preferable, 20:80 to 45:55 is further preferable, and 20:80 to 40:60 is particularly preferable.
また、共重合体(I)が構造単位(C−1)を有する場合、構造単位(C−1)の含有量は、全構造単位に対して、非特異吸着抑制や標的物質捕捉性能等の観点から、好ましくは10質量%以上、より好ましくは20質量%以上、更に好ましくは30質量%以上、更に好ましくは40質量%以上、特に好ましくは50質量%以上であり、また、非特異吸着抑制や標的物質捕捉性能等の観点から、好ましくは90質量%以下、より好ましくは80質量%以下、更に好ましくは70質量%以下、特に好ましくは60質量%以下である。 Moreover, when copolymer (I) has a structural unit (C-1), content of a structural unit (C-1) is nonspecific adsorption | suction suppression, target substance capture performance, etc. with respect to all the structural units. From the viewpoint, it is preferably 10% by mass or more, more preferably 20% by mass or more, still more preferably 30% by mass or more, still more preferably 40% by mass or more, and particularly preferably 50% by mass or more. And 90% by mass or less, more preferably 80% by mass or less, still more preferably 70% by mass or less, and particularly preferably 60% by mass or less from the viewpoints of target substance capturing performance and the like.
また、共重合体(I)が構造単位(C−2)を有する場合、構造単位(C−2)の含有量は、全構造単位に対して、好ましくは10質量%以上、より好ましくは20質量%以上、特に好ましくは30質量%以上であり、また、好ましくは90質量%以下、より好ましくは80質量%以下、特に好ましくは70質量%以下である。 Moreover, when copolymer (I) has a structural unit (C-2), content of a structural unit (C-2) becomes like this. Preferably it is 10 mass% or more with respect to all the structural units, More preferably, it is 20 It is at least 30% by mass, particularly preferably at least 30% by mass, preferably at most 90% by mass, more preferably at most 80% by mass, particularly preferably at most 70% by mass.
また、共重合体(I)が構造単位(C−3)を有する場合、構造単位(C−3)の含有量は、全構造単位に対して、非特異吸着抑制や標的物質捕捉性能等の観点から、好ましくは1質量%以上、より好ましくは3質量%以上であり、また、非特異吸着抑制や標的物質捕捉性能等の観点から、好ましくは70質量%以下、より好ましくは30質量%以下、特に好ましくは15質量%以下である。 Moreover, when copolymer (I) has a structural unit (C-3), content of a structural unit (C-3) is nonspecific adsorption | suction suppression, target substance capture performance, etc. with respect to all the structural units. From the viewpoint, it is preferably 1% by mass or more, more preferably 3% by mass or more, and from the viewpoints of non-specific adsorption suppression and target substance capturing performance, etc., preferably 70% by mass or less, more preferably 30% by mass or less. Especially preferably, it is 15 mass% or less.
また、共重合体(I)は、上記構造単位(A)〜(C)以外の構造単位(以下、構造単位(D)とも称する)を有していてもよい。
構造単位(D)としては、例えば、双性イオン構造を有するモノマー以外の親水性モノマーに由来する構造単位が挙げられる。より具体的には、メトキシポリエチレングリコール#400メタクリレート(新中村化学工業)等に由来する構造単位等である。The copolymer (I) may have a structural unit other than the structural units (A) to (C) (hereinafter also referred to as a structural unit (D)).
Examples of the structural unit (D) include structural units derived from hydrophilic monomers other than monomers having a zwitterionic structure. More specifically, structural units derived from methoxypolyethylene glycol # 400 methacrylate (Shin Nakamura Chemical Co., Ltd.) and the like.
また、共重合体(I)が架橋構造を有していない場合、数平均分子量(Mn)としては、5,000〜1,000,000が好ましく、10,000〜500,000がより好ましい。
また、共重合体(I)が架橋構造を有していない場合、重量平均分子量(Mw)としては、5,000〜1,000,000が好ましく、10,000〜500,000がより好ましい。
また、共重合体(I)が架橋構造を有していない場合、分子量分布(Mw/Mn)としては、1.0〜3.0が好ましい。
なお、数平均分子量、重量平均分子量は、ゲル浸透クロマトグラフィーで測定したポリエチレングリコール換算の平均分子量を意味する。Moreover, when copolymer (I) does not have a crosslinked structure, as a number average molecular weight (Mn), 5,000-1,000,000 are preferable and 10,000-500,000 are more preferable.
Moreover, when copolymer (I) does not have a crosslinked structure, as a weight average molecular weight (Mw), 5,000-1,000,000 are preferable and 10,000-500,000 are more preferable.
Moreover, when copolymer (I) does not have a crosslinked structure, as molecular weight distribution (Mw / Mn), 1.0-3.0 are preferable.
In addition, a number average molecular weight and a weight average molecular weight mean the average molecular weight of polyethylene glycol conversion measured by gel permeation chromatography.
また、共重合体(I)中の構造単位の配列の態様は特に限定されず、ランダム共重合体、ブロック共重合体、交互共重合体のいずれであってもよいが、簡便な手法で製造できる点等から、ランダム共重合体が好ましい。 In addition, the arrangement of the structural units in the copolymer (I) is not particularly limited and may be any of a random copolymer, a block copolymer, and an alternating copolymer. Random copolymers are preferred from the standpoints that can be made.
本発明の固相担体は、上記共重合体(I)が少なくとも固相の表面を形成するものであれば、固相(基材)そのものが共重合体(I)を含むものでも、共重合体(I)で固相(基材)が物理的に被覆されたものでもよい。
また、固相の基材(原料担体)は、有機物でも金属や金属酸化物等の無機物でもよく特に限定されないが、樹脂を含むものが好ましい。樹脂としては、アガロース、デキストラン、セルロース等の多糖類で構成される天然高分子でもよく、合成高分子でもよい。
また、本発明の固相担体の形態は特に限定されるものではなく、粒子、モノリス、膜、繊維、チップ等のいずれでもよいが、粒子が好ましく、磁性粒子がより好ましい。本発明の固相担体が、粒子、特に磁性粒子の形態の場合には、優れた再分散性が発揮され、検出・分離等の操作を大幅に簡便化できる。なお、本明細書において「磁性粒子」とは、磁性体を有する粒子を意味する。The solid phase carrier of the present invention is not limited so long as the copolymer (I) forms at least the surface of the solid phase, even if the solid phase (base material) itself contains the copolymer (I). The solid phase (base material) may be physically coated with the combined body (I).
Further, the solid phase substrate (raw material carrier) may be an organic material or an inorganic material such as a metal or a metal oxide, and is not particularly limited, but preferably includes a resin. The resin may be a natural polymer composed of a polysaccharide such as agarose, dextran, or cellulose, or may be a synthetic polymer.
Further, the form of the solid phase carrier of the present invention is not particularly limited and may be any of particles, monoliths, membranes, fibers, chips, etc., but particles are preferable, and magnetic particles are more preferable. When the solid phase carrier of the present invention is in the form of particles, particularly magnetic particles, excellent redispersibility is exhibited, and operations such as detection and separation can be greatly simplified. In the present specification, the “magnetic particle” means a particle having a magnetic material.
また、磁性体は、強磁性、常磁性、超常磁性のいずれであってもよいが、磁場による分離と磁場を取り除いた後の再分散を容易にする観点から、超常磁性であることが好ましい。磁性体としては、フェライト、酸化鉄、鉄、酸化マンガン、マンガン、酸化ニッケル、ニッケル、酸化コバルト、コバルト等の金属、又は合金が挙げられる。
また、磁性粒子としては、具体的には、以下の(i)〜(iv)のいずれかの粒子の少なくとも表面を、上記共重合体(I)が形成するものが挙げられる。好ましくは多孔質又は非多孔質の磁性ポリマー粒子である。The magnetic material may be ferromagnetic, paramagnetic, or superparamagnetic, but is preferably superparamagnetic from the viewpoint of facilitating separation by a magnetic field and redispersion after removing the magnetic field. Examples of the magnetic material include metals such as ferrite, iron oxide, iron, manganese oxide, manganese, nickel oxide, nickel, cobalt oxide, and cobalt, or alloys.
Specific examples of the magnetic particles include those in which the copolymer (I) forms at least the surface of any of the following particles (i) to (iv). Porous or non-porous magnetic polymer particles are preferred.
(i)樹脂等の非磁性体を含む連続相中に磁性体微粒子が分散している粒子
(ii)磁性体微粒子の2次凝集体をコアとし、樹脂等の非磁性体をシェルとする粒子
(iii)樹脂等の非磁性体で構成される核粒子と、該核粒子の表面に設けられた磁性体微粒子を含む磁性体層(2次凝集体層)とを有する母粒子をコアとし、該母粒子の最外層に、樹脂等の非磁性体層がシェルとして設けられた粒子
(iv)粒子の最外層に樹脂等の非磁性体層がシェルとして設けられていてもよい、樹脂やシリカ等からなる多孔質粒子の孔内に磁性体微粒子が分散している粒子
また、(i)〜(iv)の粒子の数平均粒子径は、好ましくは0.05〜250μmであり、より好ましくは0.1〜50μmであり、特に好ましくは0.1〜25μmである。なお、(i)〜(iv)の粒子はいずれも公知であり、常法に従い製造可能である。(I) Particles in which magnetic fine particles are dispersed in a continuous phase containing a non-magnetic material such as a resin (ii) Particles having a secondary aggregate of magnetic fine particles as a core and a non-magnetic material such as a resin as a shell (Iii) Core particles having core particles composed of a non-magnetic material such as a resin and a magnetic layer (secondary aggregate layer) containing magnetic fine particles provided on the surface of the core particles are used as a core. Particles in which a non-magnetic layer such as resin is provided as a shell on the outermost layer of the mother particle (iv) A resin or silica in which a non-magnetic layer such as resin is provided as a shell on the outermost layer of the particle Particles in which magnetic fine particles are dispersed in pores of porous particles made of, etc. The number average particle diameter of the particles (i) to (iv) is preferably 0.05 to 250 μm, more preferably It is 0.1-50 micrometers, Most preferably, it is 0.1-25 micrometers. The particles (i) to (iv) are all known and can be produced according to a conventional method.
上記(i)〜(iv)における樹脂は特に限定されないが、例えば、単官能性モノマー及び多官能性モノマーから選ばれる1種又は2種以上に由来する樹脂が挙げられる。
単官能性モノマーとしては、例えば、スチレン、α−メチルスチレン、ハロゲン化スチレン等の単官能性芳香族ビニル系モノマー;メチル(メタ)アクリレート、エチル(メタ)アクリレート、ステアリル(メタ)アクリレート、シクロヘキシル(メタ)アクリレート、イソボルニル(メタ)アクリレート、グリシジル(メタ)アクリレート、アリルグリシジルエーテル、2−アミノエチル(メタ)アクリレート、1,4−シクロヘキサンジメタノールモノ(メタ)アクリレート等の単官能性(メタ)アクリレート系モノマーが挙げられる。多官能性モノマーとしては、例えば、ジビニルベンゼン等の多官能性芳香族ビニル系モノマー;エチレングリコールジ(メタ)アクリレート、トリメチロールプロパントリ(メタ)アクリレート、ジペンタエリスリトールヘキサ(メタ)メタクリレート、アリル(メタ)アクリレート等の多官能性(メタ)アクリレート系モノマー;ブタジエン、イソプレン等の共役ジオレフィン等が挙げられる。Although the resin in said (i)-(iv) is not specifically limited, For example, resin derived from 1 type, or 2 or more types chosen from a monofunctional monomer and a polyfunctional monomer is mentioned.
Examples of the monofunctional monomer include monofunctional aromatic vinyl monomers such as styrene, α-methylstyrene, and halogenated styrene; methyl (meth) acrylate, ethyl (meth) acrylate, stearyl (meth) acrylate, cyclohexyl ( Monofunctional (meth) acrylates such as (meth) acrylate, isobornyl (meth) acrylate, glycidyl (meth) acrylate, allyl glycidyl ether, 2-aminoethyl (meth) acrylate, 1,4-cyclohexanedimethanol mono (meth) acrylate Based monomers. Examples of the polyfunctional monomer include polyfunctional aromatic vinyl monomers such as divinylbenzene; ethylene glycol di (meth) acrylate, trimethylolpropane tri (meth) acrylate, dipentaerythritol hexa (meth) methacrylate, allyl ( Examples thereof include polyfunctional (meth) acrylate monomers such as (meth) acrylate; conjugated diolefins such as butadiene and isoprene.
また、本発明の固相担体が粒子の場合の平均粒径(体積平均粒径)は、好ましくは0.02〜500μmであり、より好ましくは0.1〜250μmであり、更に好ましくは0.2〜100μmであり、更に好ましくは0.3〜50μmである。斯様な範囲とすることにより、固相担体が磁性粒子である場合に集磁速度が速くなりハンドリング性が改善される。また、本発明の固相担体は、平均粒径が0.05〜0.3μm程度の比較的小さい粒子である場合でも、良好な再分散性が得られる。
また、平均粒径の変動係数は、20%以下程度であればよい。
また、比表面積は、1.0〜2.0m2/g程度であればよい。
なお、上記平均粒径及び比表面積は、レーザー回析・散乱粒子径分布測定等により測定できる。The average particle diameter (volume average particle diameter) when the solid phase carrier of the present invention is a particle is preferably 0.02 to 500 μm, more preferably 0.1 to 250 μm, and still more preferably 0.8. It is 2-100 micrometers, More preferably, it is 0.3-50 micrometers. By setting it as such a range, when a solid-phase support | carrier is a magnetic particle, a magnetic flux collection speed becomes quick and handling property is improved. Moreover, even when the solid phase carrier of the present invention is a relatively small particle having an average particle size of about 0.05 to 0.3 μm, good redispersibility can be obtained.
Further, the coefficient of variation of the average particle diameter may be about 20% or less.
Moreover, the specific surface area should just be about 1.0-2.0 m < 2 > / g.
The average particle size and specific surface area can be measured by laser diffraction / scattered particle size distribution measurement or the like.
次に、本発明の固相担体の製造方法について説明する。
本発明の固相担体は、例えば、双性イオン構造を有するモノマー:全モノマーに対して1〜35質量%と、リガンドと化学結合可能な官能基を有するモノマー:全モノマーに対して70質量%以下と、リガンドと化学結合可能な官能基を有さない水難溶性モノマーとを、原料担体(基材)の存在下でラジカル重合させる工程を含む方法により製造できる。Next, a method for producing the solid phase carrier of the present invention will be described.
The solid phase carrier of the present invention is, for example, a monomer having a zwitterionic structure: 1 to 35% by mass with respect to the total monomer, and a monomer having a functional group capable of chemically bonding to the ligand: 70% by mass with respect to the total monomer. The following can be produced by a method including radical polymerization of a poorly water-soluble monomer having no functional group capable of chemically bonding to a ligand in the presence of a raw material carrier (base material).
ラジカル重合は、特開2008−191128号公報等を参考にして常法に従い行えばよいが、乳化重合、懸濁重合等が好ましく、簡便性及び容易性等の観点から、乳化重合がより好ましく、水中油型(O/W)の乳化重合が特に好ましい。具体的には、原料担体を分散させた水系媒体(水等)中に上記モノマーを含むプレエマルジョンを滴下して重合させる方法が挙げられる。 Radical polymerization may be carried out according to a conventional method with reference to JP-A-2008-191128, etc., but emulsion polymerization, suspension polymerization and the like are preferable, and emulsion polymerization is more preferable from the viewpoint of simplicity and ease, Oil-in-water (O / W) emulsion polymerization is particularly preferred. Specifically, a method may be mentioned in which a pre-emulsion containing the above monomer is dropped into an aqueous medium (water or the like) in which a raw material carrier is dispersed and polymerized.
また、ラジカル重合は、アゾ系開始剤、過酸化物系開始剤、レドックス系開始剤等の重合開始剤;アルキル硫酸エステル塩、アルキルアリール硫酸エステル塩、アルキルリン酸エステル塩、脂肪酸塩等の界面活性剤等を用いて行うのが好ましい。
また、重合温度は、通常40〜100℃であり、好ましくは50〜90℃である。また、重合時間は通常1〜48時間である。In addition, radical polymerization is performed by polymerization initiators such as azo initiators, peroxide initiators, and redox initiators; interfaces such as alkyl sulfate esters, alkylaryl sulfate esters, alkyl phosphate esters, and fatty acid salts. It is preferable to use an activator or the like.
Moreover, superposition | polymerization temperature is 40-100 degreeC normally, Preferably it is 50-90 degreeC. The polymerization time is usually 1 to 48 hours.
そして、本発明の固相担体は、簡便な手法で製造でき、しかも、非特異吸着が発生しにくく、リガンドを結合した場合に優れた標的物質捕捉性能を示すため、本発明の固相担体にリガンドを結合して用いることによって、高感度且つ低ノイズで標的物質の検出等を行うことができる。また、標的物質の分離を高純度化することができる。
したがって、本発明の固相担体をアフィニティー担体とすることで、酵素免疫測定、放射免疫測定、化学発光免疫測定等の抗原抗体反応を利用したイムノアッセイ;タンパク質、核酸等の検出;細胞、タンパク質、核酸等の生体関連物質のバイオセパレーション;薬物探索;バイオセンサー等をはじめとする、体外診断や生化学分野における研究等に広く利用できる。本発明の固相担体は、イムノアッセイのため、或いは核酸検出のための使用に特に適する。The solid phase carrier of the present invention can be produced by a simple method, is less likely to cause non-specific adsorption, and exhibits excellent target substance capture performance when bound to a ligand. By binding and using a ligand, a target substance can be detected with high sensitivity and low noise. In addition, the separation of the target substance can be highly purified.
Therefore, by using the solid phase carrier of the present invention as an affinity carrier, immunoassay utilizing antigen-antibody reaction such as enzyme immunoassay, radioimmunoassay, chemiluminescence immunoassay; detection of protein, nucleic acid, etc .; cell, protein, nucleic acid It can be widely used for in-vitro diagnosis and research in the field of biochemistry such as bioseparation of bio-related substances such as; The solid phase carriers of the present invention are particularly suitable for use for immunoassays or for nucleic acid detection.
〔リガンド結合固相担体〕
本発明のリガンド結合固相担体は、本発明の固相担体にリガンドを結合させてなるものである。
上記リガンドは、標的物質と結合する分子であればよいが、例えば、抗体;抗原;DNA、RNA等の核酸;ヌクレオチド;ヌクレオシド;プロテインA、プロテインG、(ストレプト)アビジン、酵素、レクチン等のタンパク質;インシュリン等のペプチド;アミノ酸;ヘパリン等の糖又は多糖;脂質;ビオチン等のビタミン;薬物;基質;ホルモン;神経伝達物質等が挙げられる。
これらの中でも、診断薬用等に適したリガンド結合固相担体とする観点からは、抗体、抗原が好ましい。抗体、抗原は標的物質と結合するものであればよいが、例えば、抗アンチプラスミン抗体、抗Dダイマー抗体、抗FDP抗体、抗tPA抗体、抗トロンビン・アンチトロンビン複合体抗体、抗FPA抗体等の凝固線溶関連検査用抗体又はこれに対する抗原;抗BFP抗体、抗CEA抗体、抗AFP抗体、抗TSH抗体、抗フェリチン抗体、抗CA19−9抗体等の腫瘍関連検査用抗体又はこれに対する抗原;抗アポリポタンパク抗体、抗β2−ミクロブロブリン抗体、抗α1―ミクログロブリン抗体、抗免疫グロブリン抗体、抗CRP抗体等の血清蛋白関連検査用抗体又はこれに対する抗原;抗HCG抗体等の内分泌機能検査用抗体又はこれに対する抗原;抗ジゴキシン抗体、抗リドカイン抗体等の薬物分析用抗体又はこれに対する抗原;HBs抗原、HCV抗原、HIV−1抗原、HIV−2抗原、HTLV−1抗原、マイコプラズマ抗原、トキソプラズマ抗原、ストレプトリジンO抗原等の感染症関連検査用抗原又はこれに対する抗体;DNA抗原、熱変成ヒトIgG等の自己免疫関連検査用抗原又はこれに対する抗体等が挙げられる。なお、抗体は、ポリクローナル抗体でもモノクローナル抗体でもよい。[Ligand-bound solid support]
The ligand-bound solid phase carrier of the present invention is obtained by binding a ligand to the solid phase carrier of the present invention.
The ligand may be a molecule that binds to a target substance. For example, antibody; antigen; nucleic acid such as DNA and RNA; nucleotide; nucleoside; protein such as protein A, protein G, (strept) avidin, enzyme, and lectin Peptides such as insulin; amino acids; sugars or polysaccharides such as heparin; lipids; vitamins such as biotin; drugs; substrates; hormones;
Among these, antibodies and antigens are preferable from the viewpoint of forming a ligand-bound solid phase carrier suitable for diagnostic drugs and the like. The antibody and the antigen may be any substance that binds to a target substance. For example, anti-antiplasmin antibody, anti-D dimer antibody, anti-FDP antibody, anti-tPA antibody, anti-thrombin / antithrombin complex antibody, anti-FPA antibody, etc. Anticoagulation / fibrinolysis-related antibody or antigen thereto; anti-BFP antibody, anti-CEA antibody, anti-AFP antibody, anti-TSH antibody, anti-ferritin antibody, anti-CA19-9 antibody or other anti-tumor-related antibody or antigen thereto; Serum protein-related testing antibodies such as apolipoprotein antibodies, anti-β2-microbrovulin antibodies, anti-α1-microglobulin antibodies, anti-immunoglobulin antibodies, anti-CRP antibodies, and antigens thereto; endocrine function testing antibodies such as anti-HCG antibodies Or an antigen thereto; an antibody for drug analysis such as an anti-digoxin antibody or an anti-lidocaine antibody or an antigen thereto; HB s antigens, HCV antigens, HIV-1 antigens, HIV-2 antigens, HTLV-1 antigens, mycoplasma antigens, toxoplasma antigens, streptridine O antigens and other infectious disease-related test antigens or antibodies thereto; DNA antigens, heat-denatured humans Examples include antigens for autoimmunity-related examinations such as IgG or antibodies to the same. The antibody may be a polyclonal antibody or a monoclonal antibody.
リガンド結合量は、リガンド結合固相担体の固形分1mgあたり、好ましくは1〜200μg、より好ましくは1〜100μg、更に好ましくは1〜50μg、特に好ましくは1〜30μgである。
リガンド結合量は、後述する実施例に記載の方法に従い測定できる。The amount of ligand binding is preferably 1 to 200 μg, more preferably 1 to 100 μg, still more preferably 1 to 50 μg, and particularly preferably 1 to 30 μg per 1 mg of the solid content of the ligand-bound solid phase carrier.
The amount of ligand binding can be measured according to the method described in Examples described later.
リガンドの結合は常法に従い行えばよいが、共有結合法で行うのが好ましい。例えば、リガンドと化学結合可能な官能基がカルボキシ基であり、リガンドがアミノ基を有するものである場合は、脱水縮合剤を用いて結合させればよい。 Ligand binding may be performed according to a conventional method, but is preferably performed by a covalent bond method. For example, when the functional group that can be chemically bonded to the ligand is a carboxy group and the ligand has an amino group, the ligand may be bonded using a dehydrating condensing agent.
本発明のリガンド結合固相担体は、体外診断や生化学分野における研究等に広く利用できる。本発明のリガンド結合固相担体は、イムノアッセイのため、或いは核酸検出のための使用に特に適する。 The ligand-bound solid phase carrier of the present invention can be widely used for in vitro diagnosis and research in the field of biochemistry. The ligand-bound solid support of the present invention is particularly suitable for use for immunoassays or for nucleic acid detection.
〔標的物質の検出又は分離方法〕
本発明の試料中の標的物質を検出又は分離する方法は、本発明のリガンド結合固相担体を用いることを特徴とするものである。[Target substance detection or separation method]
A method for detecting or separating a target substance in a sample of the present invention is characterized by using the ligand-bound solid phase carrier of the present invention.
標的物質はリガンドと結合するものであればよいが、具体的には、抗原;モノクローナル抗体、ポリクローナル抗体等の抗体;細胞(正常細胞、及び大腸がん細胞、血中循環がん細胞等のがん細胞);DNA、RNA等の核酸;タンパク質、ペプチド、アミノ酸、糖、多糖、脂質、ビタミン等の生体関連物質が挙げられ、創薬ターゲットとなる薬物、ビオチン等の小分子化合物でもよい。なお、標的物質は、蛍光物質などにより標識化されたものでもよい。
なお、試料は、上記標的物質を含むもの又は標的物質を含む可能性があるものであればよく、具体的には、血液、血漿、血清、標的物質を含有するバッファー溶液等である。The target substance may be any substance that binds to a ligand. Specifically, antigens; antibodies such as monoclonal antibodies and polyclonal antibodies; cells (normal cells, colon cancer cells, circulating cancer cells in the blood, etc.) Cells); nucleic acids such as DNA and RNA; bio-related substances such as proteins, peptides, amino acids, sugars, polysaccharides, lipids, and vitamins. Drugs that are drug targets, and small molecule compounds such as biotin. The target substance may be labeled with a fluorescent substance or the like.
The sample only needs to contain the target substance or may contain the target substance, and specifically, blood, plasma, serum, a buffer solution containing the target substance, and the like.
本発明の検出又は分離方法は、本発明のリガンド結合固相担体を用いる以外は常法にしたがって行えばよい。例えば、本発明のリガンド結合固相担体と標的物質を含む試料を、混合するなどして接触させる工程(接触工程)、及び標的物質を捕捉したリガンド結合固相担体を、磁石などを用いて試料から分離する工程(分離工程)を含む方法が挙げられる。なお、当該分離工程の後に、標的物質を検出する工程、又はリガンドと標的物質を解離させる工程を含んでいてもよい。 The detection or separation method of the present invention may be performed according to a conventional method except that the ligand-bound solid phase carrier of the present invention is used. For example, the step of bringing the sample containing the ligand-binding solid phase carrier of the present invention and the target substance into contact with each other (contacting step), and the ligand-binding solid phase carrier capturing the target substance using a magnet or the like The method including the process (separation process) which isolate | separates from is mentioned. Note that, after the separation step, a step of detecting the target substance or a step of dissociating the ligand and the target substance may be included.
以下、実施例を挙げて本発明を詳細に説明するが、本発明はこれら実施例に限定されるものではない。 EXAMPLES Hereinafter, although an Example is given and this invention is demonstrated in detail, this invention is not limited to these Examples.
<リガンドと化学結合可能な官能基(反応性官能基)の含有量>
粒子から遊離させた鎖状ポリマーに含まれる反応性官能基(カルボキシ基)の含有量を、電気伝導度測定法(Metrohm社、794 Basic Titrino)を用いて測定することで、粒子固形分1gあたりの反応性官能基の含有量を求めた。<Content of functional group (reactive functional group) capable of chemically bonding with ligand>
By measuring the content of the reactive functional group (carboxy group) contained in the chain polymer released from the particles using an electrical conductivity measurement method (Metrohm, 794 Basic Titrino), The content of the reactive functional group was determined.
<体積平均粒径>
各粒子の体積平均粒径は、レーザー回析・散乱粒子径分布測定装置(Beckman Coulter LS13 320)にて測定した。<Volume average particle diameter>
The volume average particle size of each particle was measured with a laser diffraction / scattered particle size distribution measuring apparatus (Beckman Coulter LS13 320).
〔合成例1〕
油性磁性流体(「EXPシリーズ、EMG」、(株)フェローテック製)にアセトンを加えて粒子を析出沈殿させた後、これを乾燥することにより、疎水化処理された表面を有するフェライト系の磁性体微粒子(平均一次粒子径:0.01μm)を得た。
次いで、ポリスチレン粒子(数平均粒子径:0.77μm)30g及び上記疎水化処理された磁性体微粒子15gをミキサーでよく混合し、この混合物をハイブリダイゼーションシステムNHS−0型((株)奈良機械製作所製)を使用して、羽根(撹拌翼)の周速度100m/秒(16,200rpm)で5分間処理し、磁性体微粒子からなる磁性体層を表面に有する母粒子(数平均粒子径:1.0μm)を得た。[Synthesis Example 1]
Ferrite magnetic material having a hydrophobized surface by adding acetone to oily magnetic fluid ("EXP series, EMG", manufactured by Ferrotec Co., Ltd.) to precipitate particles and drying them. Body fine particles (average primary particle size: 0.01 μm) were obtained.
Next, 30 g of polystyrene particles (number average particle diameter: 0.77 μm) and 15 g of the above-mentioned hydrophobized magnetic fine particles were mixed well with a mixer, and this mixture was mixed with a hybridization system NHS-0 type (Nara Machinery Co., Ltd.). For 5 minutes at a peripheral speed of 100 m / sec (16,200 rpm) of a blade (stirring blade), and a mother particle (number average particle diameter: 1) having a magnetic layer made of magnetic fine particles on the surface. 0.0 μm) was obtained.
〔実施例1〕
ドデシル硫酸ナトリウム0.50質量%水溶液300gを500mLセパラブルフラスコに投入し、次いで、合成例1で得た母粒子10gを加え、ホモジナイザーで分散した後、60℃に加熱し温度を保持した。
次に別の容器に、ドデシル硫酸ナトリウム0.50質量%水溶液45g、[2−(メタクリロイルオキシ)エチル](カルボキシラトメチル)ジメチルアミニウム(以下、「CBMA」という。)0.5g、2−メタクリロイルオキシエチルコハク酸(以下、「SA」という。)2.0g、テトラヒドロフルフリルメタクリレート(以下、「THFMA」という。)3.5g、トリメチロールプロパントリメタクリレート(以下、「TMP」という。)0.5g、及びジ(3,5,5−トリメチルヘキサノイル)パーオキサイド75%溶液(パーロイル355−75(S) 日油(株)製(以下、「パーロイル355−75(S)」という。))0.15gを入れて分散させプレエマルジョンを得た。このプレエマルジョンを、60℃に保持した上記500mLセパラブルフラスコに2時間かけて全量滴下した。滴下終了後、60℃に保持し2時間撹拌した。次いで、上記500mLセパラブルフラスコ中の粒子を、磁気を用いて分離した後、蒸留水を用いて繰り返し洗浄した。得られた粒子の体積平均粒径は、1.2μmであった。[Example 1]
300 g of a 0.50 mass% aqueous solution of sodium dodecyl sulfate was put into a 500 mL separable flask, 10 g of the mother particles obtained in Synthesis Example 1 were added, and the mixture was dispersed with a homogenizer, and then heated to 60 ° C. to maintain the temperature.
Next, in another container, 45 g of a 0.50 mass% aqueous solution of sodium dodecyl sulfate, 0.5 g of [2- (methacryloyloxy) ethyl] (carboxylatomethyl) dimethylaminium (hereinafter referred to as “CBMA”), 2- Methacryloyloxyethyl succinic acid (hereinafter referred to as “SA”) 2.0 g, tetrahydrofurfuryl methacrylate (hereinafter referred to as “THFMA”) 3.5 g, trimethylolpropane trimethacrylate (hereinafter referred to as “TMP”) 0 0.5 g, and di (3,5,5-trimethylhexanoyl) peroxide 75% solution (Perroyl 355-75 (S) manufactured by NOF Corporation (hereinafter referred to as “Parroyl 355-75 (S)”) ) 0.15 g was added and dispersed to obtain a pre-emulsion. The entire amount of this pre-emulsion was dropped into the 500 mL separable flask maintained at 60 ° C. over 2 hours. After completion of dropping, the mixture was kept at 60 ° C. and stirred for 2 hours. Next, the particles in the 500 mL separable flask were separated using magnetism, and then repeatedly washed with distilled water. The volume average particle diameter of the obtained particles was 1.2 μm.
〔実施例2〕
プレエマルジョンを作製するための原料として、ドデシル硫酸ナトリウム0.50質量%水溶液45g、CBMA1.0g、SA2.0g、THFMA3.0g、TMP0.5g、及びパーロイル355−75(S)0.15gを使用した以外は、実施例1と同様の操作を行った。得られた粒子の体積平均粒径は、1.2μmであった。[Example 2]
As raw materials for preparing the pre-emulsion, 45 g of sodium dodecyl sulfate 0.50 mass% aqueous solution, CBMA 1.0 g, SA 2.0 g, THFMA 3.0 g, TMP 0.5 g, and Parroyl 355-75 (S) 0.15 g are used. Except that, the same operation as in Example 1 was performed. The volume average particle diameter of the obtained particles was 1.2 μm.
〔実施例3〕
プレエマルジョンを作製するための原料として、ドデシル硫酸ナトリウム0.50質量%水溶液45g、CBMA2.0g、SA2.0g、THFMA2.0g、TMP0.5g、及びパーロイル355−75(S)0.15gを使用した以外は、実施例1と同様の操作を行った。得られた粒子の体積平均粒径は、1.2μmであった。Example 3
As raw materials for preparing the pre-emulsion, 45 g of sodium dodecyl sulfate 0.50 mass% aqueous solution, CBMA 2.0 g, SA 2.0 g, THFMA 2.0 g, TMP 0.5 g, and Parroyl 355-75 (S) 0.15 g are used. Except that, the same operation as in Example 1 was performed. The volume average particle diameter of the obtained particles was 1.2 μm.
〔実施例4〕
プレエマルジョンを作製するための原料として、ドデシル硫酸ナトリウム0.50質量%水溶液45g、CBMA0.5g、SA2.0g、シクロヘキシルメタクリレート(以下、「CHMA」という)3.5g、TMP0.5g、及びパーロイル355−75(S)0.15gを使用した以外は、実施例1と同様の操作を行った。得られた粒子の体積平均粒径は、1.2μmであった。Example 4
As raw materials for preparing a pre-emulsion, 45 g of sodium dodecyl sulfate 0.50 mass% aqueous solution, CBMA 0.5 g, SA 2.0 g, 3.5 g of cyclohexyl methacrylate (hereinafter referred to as “CHMA”), TMP 0.5 g, and Parroyl 355 The same operation as in Example 1 was performed except that 0.15 g of -75 (S) was used. The volume average particle diameter of the obtained particles was 1.2 μm.
〔実施例5〕
プレエマルジョンを作製するための原料として、ドデシル硫酸ナトリウム0.50質量%水溶液45g、CBMA0.5g、SA1.0g、THFMA4.5g、TMP0.5g、及びパーロイル355−75(S)0.15gを使用した以外は、実施例1と同様の操作を行った。得られた粒子の体積平均粒径は、1.2μmであった。Example 5
As raw materials for preparing the pre-emulsion, 45 g of sodium dodecyl sulfate 0.50 mass% aqueous solution, CBMA 0.5 g, SA 1.0 g, THFMA 4.5 g, TMP 0.5 g, and Parroyl 355-75 (S) 0.15 g are used. Except that, the same operation as in Example 1 was performed. The volume average particle diameter of the obtained particles was 1.2 μm.
〔実施例6〕
プレエマルジョンを作製するための原料として、ドデシル硫酸ナトリウム0.50質量%水溶液45g、CBMA0.5g、SA3.0g、THFMA2.5g、TMP0.5g、及びパーロイル355−75(S)0.15gを使用した以外は、実施例1と同様の操作を行った。得られた粒子の体積平均粒径は、1.2μmであった。Example 6
As raw materials for preparing pre-emulsion, 45 g of sodium dodecyl sulfate 0.50 mass% aqueous solution, CBMA 0.5 g, SA 3.0 g, THFMA 2.5 g, TMP 0.5 g, and Parroyl 355-75 (S) 0.15 g are used. Except that, the same operation as in Example 1 was performed. The volume average particle diameter of the obtained particles was 1.2 μm.
〔実施例7〕
プレエマルジョンを作製するための原料として、ドデシル硫酸ナトリウム0.50質量%水溶液45g、CBMA0.5g、SA2.0g、THFMA4.0g、及びパーロイル355−75(S)0.15gを使用した以外は、実施例1と同様の操作を行った。得られた粒子の体積平均粒径は、1.2μmであった。Example 7
As a raw material for preparing the pre-emulsion, except that 45 g of sodium dodecyl sulfate 0.50 mass% aqueous solution, CBMA 0.5 g, SA 2.0 g, THFMA 4.0 g, and Parroyl 355-75 (S) 0.15 g were used. The same operation as in Example 1 was performed. The volume average particle diameter of the obtained particles was 1.2 μm.
〔実施例8〕
プレエマルジョンを作製するための原料として、ドデシル硫酸ナトリウム0.50質量%水溶液45g、O−[2−(メタクリロイルオキシ)エトキシ(オキシラト)ホスフィニル]コリン(以下、「MPC」という。)0.5g、SA2.0g、THFMA3.5g、TMP0.5g、及びパーロイル355−75(S)0.15gを使用した以外は、実施例1と同様の操作を行った。得られた粒子の体積平均粒径は、1.2μmであった。Example 8
As raw materials for preparing the pre-emulsion, 45 g of a 0.50 mass% aqueous solution of sodium dodecyl sulfate, 0.5 g of O- [2- (methacryloyloxy) ethoxy (oxylato) phosphinyl] choline (hereinafter referred to as “MPC”), The same operation as in Example 1 was performed, except that SA 2.0 g, THFMA 3.5 g, TMP 0.5 g, and Parroyl 355-75 (S) 0.15 g were used. The volume average particle diameter of the obtained particles was 1.2 μm.
〔実施例9〕
プレエマルジョンを作製するための原料として、ドデシル硫酸ナトリウム0.50質量%水溶液45g、CBMA0.5g、SA2.0g、ジエチレングリコールモノメチルエーテルメタクリレート(以下、「DEGMA」という。)3.5g、TMP0.5g、及びパーロイル355−75(S)0.15gを使用した以外は、実施例1と同様の操作を行った。得られた粒子の体積平均粒径は、1.2μmであった。Example 9
As raw materials for preparing the pre-emulsion, 45 g of sodium dodecyl sulfate 0.50 mass% aqueous solution, CBMA 0.5 g, SA 2.0 g, diethylene glycol monomethyl ether methacrylate (hereinafter referred to as “DEGMA”) 3.5 g, TMP 0.5 g, The same operation as in Example 1 was performed except that 0.15 g of Parroyl 355-75 (S) was used. The volume average particle diameter of the obtained particles was 1.2 μm.
〔実施例10〕
ドデシル硫酸ナトリウム0.50質量%水溶液300g、ヘプタン10gに分散した磁性流体EMG6g、CBMA0.5g、SA2g、THFMA3.5g、TMP0.5g、パーロイル355−75(S)0.15gを500mLセパラブルフラスコに投入し、分散させてプレエマルジョンを得たのち、60℃まで昇温して、2時間保持した。次いで、上記500mLセパラブルフラスコ中の粒子を、磁気を用いて分離した後、蒸留水を用いて繰り返し洗浄した。得られた粒子の体積平均粒径は、0.2μmであった。Example 10
300 g of magnetic fluid EMG 6 g, CBMA 0.5 g, SA 2 g, THFMA 3.5 g, TMP 0.5 g and Parroyl 355-75 (S) 0.15 g dispersed in 300 g of 0.50 mass% sodium dodecyl sulfate aqueous solution 10 g in a 500 mL separable flask The mixture was added and dispersed to obtain a pre-emulsion, and then the temperature was raised to 60 ° C. and held for 2 hours. Next, the particles in the 500 mL separable flask were separated using magnetism, and then repeatedly washed with distilled water. The volume average particle diameter of the obtained particles was 0.2 μm.
〔比較例1〕
プレエマルジョンを作製するための原料として、ドデシル硫酸ナトリウム0.50質量%水溶液45g、CBMA4.5g、SA2.0g、及びパーロイル355−75(S)0.15gを使用した以外は、実施例1と同様の操作を行った。得られた粒子の体積平均粒径は、1.2μmであった。[Comparative Example 1]
Example 1 with the exception that 45 g of 0.50% by weight sodium dodecyl sulfate aqueous solution, 4.5 g of CBMA, 2.0 g of SA, and 0.15 g of parroyl 355-75 (S) were used as raw materials for preparing the pre-emulsion. The same operation was performed. The volume average particle diameter of the obtained particles was 1.2 μm.
〔比較例2〕
プレエマルジョンを作製するための原料として、ドデシル硫酸ナトリウム0.50質量%水溶液45g、SA2.0g、THFMA4.0g、TMP0.5g、及びパーロイル355−75(S)0.15gを使用した以外は、実施例1と同様の操作を行った。得られた粒子の体積平均粒径は、1.2μmであった。[Comparative Example 2]
As the raw material for preparing the pre-emulsion, except that 45 g of sodium dodecyl sulfate 0.50 mass% aqueous solution, SA 2.0 g, THFMA 4.0 g, TMP 0.5 g, and Parroyl 355-75 (S) 0.15 g were used. The same operation as in Example 1 was performed. The volume average particle diameter of the obtained particles was 1.2 μm.
〔比較例3〕
プレエマルジョンを作製するための原料として、ドデシル硫酸ナトリウム0.50質量%水溶液45g、CBMA3.0g、SA2.0g、THFMA1.0g、TMP0.5g、及びパーロイル355−75(S)0.15gを使用した以外は、実施例1と同様の操作を行った。得られた粒子の体積平均粒径は、1.2μmであった。[Comparative Example 3]
As raw materials for preparing the pre-emulsion, 45 g of sodium dodecyl sulfate 0.50 mass% aqueous solution, CBMA 3.0 g, SA 2.0 g, THFMA 1.0 g, TMP 0.5 g, and Parroyl 355-75 (S) 0.15 g are used. Except that, the same operation as in Example 1 was performed. The volume average particle diameter of the obtained particles was 1.2 μm.
〔比較例4〕
プレエマルジョンを作製するための原料として、ドデシル硫酸ナトリウム0.50質量%水溶液45g、CBMA0.5g、SA5.0g、THFMA0.5g、TMP0.5g、及びパーロイル355−75(S)0.15gを使用した以外は、実施例1と同様の操作を行った。得られた粒子の体積平均粒径は、1.2μmであった。[Comparative Example 4]
As raw materials for preparing the pre-emulsion, 45 g of sodium dodecyl sulfate 0.50 mass% aqueous solution, CBMA 0.5 g, SA 5.0 g, THFMA 0.5 g, TMP 0.5 g, and Parroyl 355-75 (S) 0.15 g are used. Except that, the same operation as in Example 1 was performed. The volume average particle diameter of the obtained particles was 1.2 μm.
〔比較例5〕
プレエマルジョンを作製するための原料として、ドデシル硫酸ナトリウム0.50質量%水溶液300g、ヘプタン10gに分散した磁性流体EMG6g、SA2.0g、THFMA4.0g、TMP0.5g、及びパーロイル355−75(S)0.15gを使用した以外は、実施例10と同様の操作を行った。得られた粒子の体積平均粒径は、0.2μmであった。[Comparative Example 5]
As raw materials for preparing the pre-emulsion, 300 g of 0.50 mass% aqueous solution of sodium dodecyl sulfate, 6 g of magnetic fluid dispersed in 10 g of heptane, 2.0 g of SA, 4.0 g of THFMA, 0.5 g of TMP, and Parroyl 355-75 (S) The same operation as in Example 10 was performed except that 0.15 g was used. The volume average particle diameter of the obtained particles was 0.2 μm.
〔試験例1〕
各実施例及び比較例で得られた磁性粒子1mgを、水2mLにそれぞれ分散させた。この水分散液をエッペンドルフチューブに投入し、磁気を用いて粒子を分離して上清を除去した。次いで、粒子をMES緩衝液(100mM、pH5.0)990μLに分散させ、1−エチル−3−(3−ジメチルアミノプロピル)カルボジイミド塩酸塩(10mg/mL)10μLを加え、室温で30分間インキュベートした。磁気を用いて粒子を分離して上清を除去し、MES緩衝液(100mM、pH5.0)1mLに分散させ、抗TSH抗体(フナコシ社製)20μgを加えた。室温で12時間インキュベートした後、磁気を用いて粒子を分離して上清を除去した。TBS−T(0.05質量%Tween20)緩衝液で5回洗浄し、抗体結合粒子を得た。抗体結合量をBCA Assayにより求めた。結果を表2に示す。[Test Example 1]
1 mg of magnetic particles obtained in each example and comparative example were dispersed in 2 mL of water. This aqueous dispersion was put into an Eppendorf tube, particles were separated using magnetism, and the supernatant was removed. The particles were then dispersed in 990 μL of MES buffer (100 mM, pH 5.0), 10 μL of 1-ethyl-3- (3-dimethylaminopropyl) carbodiimide hydrochloride (10 mg / mL) was added and incubated for 30 minutes at room temperature. . Particles were separated using magnetism, the supernatant was removed, dispersed in 1 mL of MES buffer (100 mM, pH 5.0), and 20 μg of anti-TSH antibody (Funakoshi) was added. After incubation for 12 hours at room temperature, the particles were separated using magnetism and the supernatant was removed. The antibody-bound particles were obtained by washing 5 times with TBS-T (0.05 mass% Tween 20) buffer. The amount of antibody binding was determined by BCA Assay. The results are shown in Table 2.
〔試験例2〕
試験例1で得られた抗体結合粒子の分散液5μL(粒子50μg相当)をテストチューブに取り、ウシ胎児血清(FCS)50μLが添加された5μIU/mLのTSH抗原溶液(富士レビオ社製ルミパルスTSH−III標準TSH溶液)50μLを混合し、25℃で10分間反応させた。磁気を用いて粒子を分離し上清を除いた後、2次抗体としてアルカリフォスフォターゼで標識した抗TSH抗体(富士レビオ社製ルミパルスTSH−III免疫反応カートリッジ付属)40μLを添加し、25℃で10分間反応させた。磁気を用いて粒子を分離し上清を除いた後、PBSで3回洗浄を繰り返して得られた粒子を、50μLの0.01%TritonX−100に分散させ、新しいチューブに移し替えた。アルカリフォスフォターゼの基質液(富士レビオ社製ルミパルス基質液)100μLを加え、37℃で10分間反応させた後、シグナルとして化学発光量を測定した。化学発光の測定には、ベルトールジャパン社製の化学発光測定装置(Lumat LB9507)を用いた。また上記で、5μIU/mLのTSH抗原溶液の代わりに、0μIU/mLのTSHキャリブレータとした以外は同様にして、ノイズとして化学発光量を測定した。さらに、シグナル(S)をノイズ(N)で割った値S/Nを算出した。結果を表2に示す。[Test Example 2]
5 μL of the antibody-bound particle dispersion obtained in Test Example 1 (corresponding to 50 μg of particles) is placed in a test tube, and 5 μIU / mL TSH antigen solution (Lumipulse TSH manufactured by Fujirebio Inc.) supplemented with 50 μL of fetal calf serum (FCS) -III standard TSH solution) 50 μL was mixed and reacted at 25 ° C. for 10 minutes. After separating the particles using magnetism and removing the supernatant, 40 μL of anti-TSH antibody (attached to Lumipulse TSH-III immunoreaction cartridge manufactured by Fujirebio Inc.) labeled with alkaline phosphatase as a secondary antibody was added, and 25 ° C. For 10 minutes. After separating the particles using magnetism and removing the supernatant, the particles obtained by washing three times with PBS were dispersed in 50 μL of 0.01% Triton X-100 and transferred to a new tube. After adding 100 μL of alkaline phosphatase substrate solution (Lumipulse substrate solution manufactured by Fujirebio Inc.) and reacting at 37 ° C. for 10 minutes, the amount of chemiluminescence was measured as a signal. For the measurement of chemiluminescence, a chemiluminescence measuring apparatus (Lumat LB9507) manufactured by Bertol Japan was used. Further, the chemiluminescence amount was measured as noise in the same manner except that a 0 μIU / mL TSH calibrator was used instead of the 5 μIU / mL TSH antigen solution. Further, a value S / N obtained by dividing the signal (S) by the noise (N) was calculated. The results are shown in Table 2.
〔試験例3〕
各実施例及び比較例で得られた磁性粒子1mgを、水2mLにそれぞれ分散させ、分散液をエッペンドルフチューブに投入した。チューブを磁性ビーズ分離用スタンド(Magical Trapper(東洋紡社製))に取り付け、5分間程度静置して粒子がペレット状に集磁されたことを確認した。次いで、スタンドからチューブを取り外して粒子を磁気から解放し、1分間経過後の様子を確認し、以下の基準で評価した。評価結果を表2に示す。
<評価基準>
○:ペレットが崩れながらチューブ下部に沈降し、再分散性が良い
×:ペレットがほぼ保持され、再分散性が悪い[Test Example 3]
1 mg of the magnetic particles obtained in each Example and Comparative Example were dispersed in 2 mL of water, and the dispersion was put into an Eppendorf tube. The tube was attached to a magnetic bead separation stand (Magic Trapper (manufactured by Toyobo Co., Ltd.)) and allowed to stand for about 5 minutes to confirm that the particles were collected in a pellet form. Subsequently, the tube was removed from the stand to release the particles from the magnetism, and the state after 1 minute was confirmed and evaluated according to the following criteria. The evaluation results are shown in Table 2.
<Evaluation criteria>
○: The pellet settles in the lower part of the tube while collapsing, and the redispersibility is good.
各実施例及び比較例で得られた磁性粒子表面の共重合体を構成するモノマーの組成を、表1に示す。 Table 1 shows the composition of the monomers constituting the copolymer on the surface of the magnetic particles obtained in each Example and Comparative Example.
表2に示すとおり、実施例1〜10の磁性粒子は、S/N(シグナル/ノイズ)比が高く、高感度且つ低ノイズで抗原を検出できた。また、再分散性も良好であった。 As shown in Table 2, the magnetic particles of Examples 1 to 10 had a high S / N (signal / noise) ratio, and were able to detect antigens with high sensitivity and low noise. The redispersibility was also good.
Claims (21)
(A)双性イオン構造を有するモノマーに由来する構造単位:全構造単位に対して1〜35質量%
(B)リガンドと化学結合可能な官能基を有するモノマーに由来する構造単位:全構造単位に対して70質量%以下
(C)リガンドと化学結合可能な官能基を有さない水難溶性モノマーに由来する構造単位A solid phase carrier, wherein a copolymer comprising the following structural units (A) to (C) forms at least a solid surface.
(A) Structural unit derived from a monomer having a zwitterionic structure: 1 to 35% by mass relative to all structural units
(B) Structural unit derived from a monomer having a functional group capable of chemically binding to a ligand: 70% by mass or less based on the total structural unit (C) Derived from a poorly water-soluble monomer having no functional group capable of chemically binding to a ligand Structural unit
R11は、水素原子又はメチル基を示し、
R12は、−(C=O)−O−*、−(C=O)−NR14−*(R14は、水素原子又はメチル基を示し、*は、式(3)中のR13と結合する位置を示す)又はフェニレン基を示し、
R13は、双性イオン構造を示す。〕The solid phase carrier according to claim 1, wherein the structural unit (A) is a structural unit represented by the following formula (3).
R 11 represents a hydrogen atom or a methyl group,
R 12 represents — (C═O) —O— *, — (C═O) —NR 14 — * (R 14 represents a hydrogen atom or a methyl group, and * represents R 13 in formula (3). Or a phenylene group,
R 13 represents a zwitterionic structure. ]
R1及びR2は、それぞれ独立して、単結合又は炭素数1〜10の2価の有機基を示し、
R3は、−(C=O)O-又は−SO3 -を示し、
R4及びR5は、それぞれ独立して、メチル基又はエチル基を示す。〕
R6及びR7は、それぞれ独立して、単結合又は炭素数1〜10の2価の有機基を示し、
R8、R9及びR10は、それぞれ独立して、メチル基又はエチル基を示す。〕The solid phase carrier according to claim 1 or 2, wherein the zwitterionic structure is represented by the following formula (1) or (2).
R 1 and R 2 each independently represent a single bond or a divalent organic group having 1 to 10 carbon atoms,
R 3 represents — (C═O) O 2 — or —SO 3 — ,
R 4 and R 5 each independently represents a methyl group or an ethyl group. ]
R 6 and R 7 each independently represents a single bond or a divalent organic group having 1 to 10 carbon atoms,
R 8 , R 9 and R 10 each independently represent a methyl group or an ethyl group. ]
R15は、水素原子又はメチル基を示し、
R16は、−(C=O)−O−*、−(C=O)−NR18−*(R18は、水素原子又はメチル基を示し、*は、式(4)中のR17と結合する位置を示す)又はフェニレン基を示し、
R16が−(C=O)−O−*である場合、R17は、水素原子、又はリガンドと化学結合可能な官能基を有する有機基を示し、R16が−(C=O)−NR18−*又はフェニレン基である場合、R17は、リガンドと化学結合可能な官能基を有する有機基を示す。〕The solid phase carrier according to any one of claims 1 to 3, wherein the structural unit (B) is a structural unit represented by the following formula (4).
R 15 represents a hydrogen atom or a methyl group,
R 16 represents — (C═O) —O— *, — (C═O) —NR 18 — * (R 18 represents a hydrogen atom or a methyl group, and * represents R 17 in formula (4). Or a phenylene group,
When R 16 is — (C═O) —O— *, R 17 represents a hydrogen atom or an organic group having a functional group capable of chemically bonding to a ligand, and R 16 represents — (C═O) —. NR 18 - If a * or a phenylene group, R 17 represents an organic group having a ligand capable of chemically bonding functional groups. ]
(C−1)重合させてホモポリマーとし自由水を共存させた場合に中間水を保持するモノアクリレートモノマー又は該モノアクリレートモノマーと側鎖の構造が同一のモノメタクリレートモノマーに由来する構造単位
(C−2)下記式(7)で表されるモノ(メタ)アクリレートモノマーに由来する構造単位
R22は、水素原子又はメチル基を示し、
R23は、炭化水素基を示す。〕
(C−3)多官能性モノマーに由来する構造単位The solid support according to any one of claims 1 to 5, wherein the structural unit (C) is one or more selected from the following structural units (C-1) to (C-3). .
(C-1) A structural unit derived from a monoacrylate monomer that retains intermediate water when polymerized into a homopolymer in the presence of free water or a monomethacrylate monomer having the same side chain structure as that of the monoacrylate monomer (C -2) Structural unit derived from a mono (meth) acrylate monomer represented by the following formula (7)
R 22 represents a hydrogen atom or a methyl group,
R 23 represents a hydrocarbon group. ]
(C-3) Structural unit derived from polyfunctional monomer
R24は、水素原子又はメチル基を示し、
R25は、炭素数1〜3のアルカンジイル基を示し、
R26は、炭素数1〜3のアルキル基を示し、
nは、1〜5の整数を示す。〕
R27は、水素原子又はメチル基を示し、
mは、1又は2を示す。〕The solid phase carrier according to claim 6 or 7, wherein the structural unit (C-1) is a structural unit derived from a monomer represented by the following formula (8) or (9).
R 24 represents a hydrogen atom or a methyl group,
R 25 represents an alkanediyl group having 1 to 3 carbon atoms;
R 26 represents an alkyl group having 1 to 3 carbon atoms,
n shows the integer of 1-5. ]
R 27 represents a hydrogen atom or a methyl group,
m represents 1 or 2. ]
リガンドと化学結合可能な官能基を有するモノマー:全モノマーに対して70質量%以下と、
リガンドと化学結合可能な官能基を有さない水難溶性モノマーとを、
原料担体の存在下でラジカル重合させる工程を含むことを特徴とする、固相担体の製造方法。Monomer having zwitterionic structure: 1 to 35% by mass with respect to all monomers,
Monomer having a functional group capable of chemically binding to a ligand: 70% by mass or less based on the total monomer
A poorly water-soluble monomer having no functional group capable of chemically bonding to a ligand,
A method for producing a solid phase carrier, comprising a step of radical polymerization in the presence of a raw material carrier.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2015040092 | 2015-03-02 | ||
JP2015040092 | 2015-03-02 | ||
PCT/JP2016/056230 WO2016140216A1 (en) | 2015-03-02 | 2016-03-01 | Solid-phase support, ligand-bonding solid-phase support, target-substance detecting or separating method, and method of manufacturing solid-phase support |
Publications (2)
Publication Number | Publication Date |
---|---|
JPWO2016140216A1 true JPWO2016140216A1 (en) | 2017-12-14 |
JP6660935B2 JP6660935B2 (en) | 2020-03-11 |
Family
ID=56848182
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2017503659A Active JP6660935B2 (en) | 2015-03-02 | 2016-03-01 | Solid support, ligand-bound solid support, method for detecting or separating a target substance, and method for producing the solid support |
Country Status (2)
Country | Link |
---|---|
JP (1) | JP6660935B2 (en) |
WO (1) | WO2016140216A1 (en) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2020183946A (en) * | 2019-04-26 | 2020-11-12 | キヤノン株式会社 | Particle, affinity particle, inspection reagent, and detection method |
CN111974360B (en) * | 2019-05-24 | 2023-05-16 | 中元汇吉生物技术股份有限公司 | Magnetic microsphere, preparation method and application thereof |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2008191128A (en) * | 2007-02-08 | 2008-08-21 | Jsr Corp | Magnetic particle and probe-bound particle |
WO2011125618A1 (en) * | 2010-03-31 | 2011-10-13 | 旭化成クラレメディカル株式会社 | Substrate for ligand immobilization and method for producing same |
JP2012177691A (en) * | 2011-02-04 | 2012-09-13 | Hitachi Maxell Ltd | Magnetic marker particle |
JP2012181181A (en) * | 2011-02-10 | 2012-09-20 | Sumitomo Bakelite Co Ltd | Particle for immobilization of physiologically active substance, physiologically active substance immobilization particle and sugar affinity substance capturing particle |
-
2016
- 2016-03-01 WO PCT/JP2016/056230 patent/WO2016140216A1/en active Application Filing
- 2016-03-01 JP JP2017503659A patent/JP6660935B2/en active Active
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2008191128A (en) * | 2007-02-08 | 2008-08-21 | Jsr Corp | Magnetic particle and probe-bound particle |
WO2011125618A1 (en) * | 2010-03-31 | 2011-10-13 | 旭化成クラレメディカル株式会社 | Substrate for ligand immobilization and method for producing same |
JP2012177691A (en) * | 2011-02-04 | 2012-09-13 | Hitachi Maxell Ltd | Magnetic marker particle |
JP2012181181A (en) * | 2011-02-10 | 2012-09-20 | Sumitomo Bakelite Co Ltd | Particle for immobilization of physiologically active substance, physiologically active substance immobilization particle and sugar affinity substance capturing particle |
Also Published As
Publication number | Publication date |
---|---|
WO2016140216A1 (en) | 2016-09-09 |
JP6660935B2 (en) | 2020-03-11 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP6618916B2 (en) | Solid phase carrier, ligand-bound solid phase carrier, target substance detection or separation method, and method for producing the solid phase carrier | |
US5283079A (en) | Process to make magnetically responsive fluorescent polymer particles | |
US5395688A (en) | Magnetically responsive fluorescent polymer particles | |
AU634631B2 (en) | Magnetically responsive fluorescent polymer particles and application thereof | |
JP2736467B2 (en) | Manufacturing method of magnetically responsive polymer particles and its application | |
US6013531A (en) | Method to use fluorescent magnetic polymer particles as markers in an immunoassay | |
US10788487B2 (en) | Solid-phase support, ligand-binding solid-phase support, method for detecting or separating target substance, and method for producing the solid-phase support | |
JP6532202B2 (en) | Magnetic particle, ligand binding particle, method for detecting or separating target substance, and method for producing the magnetic particle | |
JP6289608B2 (en) | Solid phase carrier, ligand-bound solid phase carrier, target substance detection or separation method, solid phase carrier production method, and ligand-bound solid phase carrier production method | |
JP6660935B2 (en) | Solid support, ligand-bound solid support, method for detecting or separating a target substance, and method for producing the solid support | |
Nehilla et al. | A stimuli-responsive, binary reagent system for rapid isolation of protein biomarkers | |
JP4911280B2 (en) | Organic polymer particles and method for producing the same | |
JP2018146535A (en) | Method of manufacturing probe binding carrier, method of detecting or isolating target substance, probe binding carrier, and protein or nucleic acid stabilizer | |
US11366108B2 (en) | Method of producing probe-bound carrier, probe-bound carrier and method of detecting or separating target substance | |
WO2006036003A1 (en) | Microparticle having, linked thereto, substance having biospecific affinity and use thereof | |
AU2796689A (en) | Process for producing magnetically responsive polymer particles and application thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20190228 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20190917 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20191031 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20200204 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20200210 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 6660935 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |